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Abstract 
 
 
 
Surgery is the mainstay treatment of brain tumors, however complete resection 
is rarely achieved, especially when dealing with grade IV glioblastoma (GBM). GBM is 
the most lethal brain tumor worldwide with an average survival not longer than 15 
months. A reason of this dismal outcome is the lack of intraoperative visualization 
techniques for the objective identification of true tumor borders and infiltrating tumor 
cells. Hence, the improvement of GBM visualization during surgical operation is the 
motivation of this project. 
Recent developments of handheld fiber optic probes and lasers for low cost systems, 
together with sensitivity enhancement techniques such as surface enhanced Raman 
scattering (SERS), have ruled Raman spectroscopy as one of the most promising 
technologies for surgical guidance. This technique could overcome the limitations of 
current intraoperative modalities such as neuronavigation, magnetic resonance imaging 
and fluorescence guided surgery. For increased sensitivity, metallic nanostructures are 
preferred because they strongly interact with light, due to surface plasmon resonance 
(SPR), and produce a much higher level of amplification compared to flat surfaces. 
Among the nanostructures, gold nanoparticles (GNPs) have found wide application in 
SERS based imaging studies for their higher biocompatibility and versatile 
functionalization. When properly engineered, visualization can be targeted on tumor-
specific biomolecules providing an accurate mapping of tumor spread. For optimized 
intraoperative visualization of GBM, detection can be tuned to the near-infrared (NIR) 
window by acting both on the size and shape of GNPs. This enables to overcome the 
interfering autofluorescence and to reach a deeper tissue penetration. However, 
surface chemistry becomes essential to create SERS tags for a fast, sensitive and specific 
detection of tumor cells. 
Due to the absence of comprehensive studies on the impact of GNPs surface 
functionalization on SERS based imaging, this thesis elucidates the effect of Raman 
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reporter, inert protective polyethylene glycol (PEG) and anti-epidermal growth factor 
receptor (EGFR) antibody on colloidal stability, cellular binding specificity, detection 
sensitivity and speed. EGFR was the target of choice because its gene amplification is 
the most common molecular hallmark in about 60% of GBM and protein overexpression 
on cell cytoplasmic membrane makes it easily accessible.  
Based on the findings, GNPs with dense surface coverage of Raman reporter or 
PEG produced the maximum imaging sensitivity and binding specificity, respectively. 
However, GNPs with dense Raman reporter surface coverage were liable to non-specific 
binding and colloidal aggregation. Conversely, GNPs with dense PEG surface coverage 
owned the highest stability but underwent more than 90% reduction of SERS sensitivity. 
Higher integration time (from 0.05 to 0.5 sec) or shorter working distance (from 16.5 to 
0.3 mm) to counteract the decreased SERS sensitivity were not considered in view of 
the final application in vivo. GNPs with surface coverage made of 50% Raman reporter 
and 50% PEG owned the optimal mixture for an immediate Raman detection of in vitro 
human GBM cells (LN229wtEGFR, BS153 and U87MG) while minimizing non-specific 
binding on EGFR-negative cells (IMA2.1). Further, SERS signal was comparable 
independently on the different EGFR expression level or the presence of EGFRvIII in 
BS153. The latter is the constitutively active receptor whose presence is associated to 
the lack of response during fluorescence based visualization of GBM. It was also shown 
that excess of Raman reporter did not add any significant contribution to SERS 
sensitivity. Similarly, the conjugation efficiency decreased by 35% through the addition 
of 10 times the concentration of antibody, compared to the lower concentration. This 
excess quantity of antibody showed no improvement of binding affinity of GNPs to 
tumor cells. 
Because the blood brain barrier (BBB) limits the therapeutic access to brain tumor, the 
ability of GNPs to cross an in vitro BBB made of a monoculture of human endothelial 
cells (hCMEC/D3) is crucial for successful intraoperative visualization. About 0.1% of 
GNPs, with specific ratio of immobilized functionalities, was able to cross the cell 
monolayer preserving its integrity and eliciting no cytotoxic effects. Similar results were 
obtained in vivo. 
By providing an in-depth investigation, this work stresses the significance of 
identifying the appropriate surface chemistry to improve the biomedical potential of 
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GNPs in SERS based imaging applications. At the same time, it provides an in vitro 
demonstration that SERS based imaging can be implemented intraoperatively for 
immediate visualization of GBM offering an adequate alternative for the detection of 
those GBM or low-grade brain tumors that show variable or no response to fluorescence 
guided surgery, the current state-of-art for GBM intraoperative visualization. 
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1. Introduction 
 
 
 
Up to today, surgery represents the state-of-art treatment in cancer 
management [1], [2]. It aims at removing entirely the tumor or, if it is not feasible, at 
reducing its size (debulking tumor) in order to relieve the most severe symptoms and to 
make subsequent therapies more effective [3]. Complete resection works best for solid 
tumors limited in a restricted area [4]. In these cases, surgeons are able to remove the 
solid mass together with a rim of normal tissue around it to make sure that the complete 
cancer has been excised. However, resection of safety margins is not viable when 
surgeons deal with tumors located in a sensitive area such as brain where unnecessary 
removal of normal tissue can lead to impairment of neurological functions and quality 
of life. Furthermore, a sharp delineation between tumor and healthy brain tissue would 
facilitate a more complete tumor resection but remains an unmet challenge in high-
grade brain tumors as GBM. In fact, GBM has blurred tumor borders due to highly 
infiltrative tumor cells that invade the surrounding parenchyma hindering the possibility 
to remove them entirely. Investigation of brain tumor recurrences has consistently 
shown that 80-90% of these occurs within the original treatment field, identifying as the 
cause the residual tumor cells due to incomplete resection [5]. Beside subjective 
assessments such as texture palpation or visual inspection, neurosurgeons can rely on 
the use of a variety of intraoperative guidance technologies as discussed in the following 
section. 
 
1.1 Intraoperative glioblastoma guidance technologies 
For tailored surgical approach, the state-of-art methods are listed stressing the ‘pros’ 
and ‘cons’ of each. 
 
Neuronavigation is a computational process that combines pre and 
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intraoperative data creating a translation map between imaging displayed on the screen 
and real spatial position [6]. Major limitation is the positional accuracy of only 2-3 mm 
because of intraoperative brain shift due to cerebrospinal fluid loss, decompression and 
parenchyma displacement [7], [8]. 
 
 Intraoperative magnetic resonance imaging (iMRI) is based on the same principle 
as MRI, and either a specific in situ donut MRI scanner or a parallel stationary MRI 
scanner in an adjacent diagnostic room are used [6], [7]. iMRI gives accurate real-time 
information to be used for further planning optimization and assessment of the progress 
of the surgery [7]. Senft et al. showed its effectiveness: 96% of patients had complete 
tumor resection compared to 68% in the control group. Although iMRI value is 
undisputed, its use is limited due to additional operating time (average of 1 h more is 
required), equipment size and associated costs (5-8 million USD for the installation) [9]. 
Additional, low magnetic field strength neglects invasive cancer cells and repeated 
injections or dosages of gadolinium are necessary due to short blood half-life [6], [7], 
[10]. 
 
 Intraoperative ultrasonography (iUS) is helpful when the tumor is not isoechoic 
with the brain or the density difference is greater [11]. Freehand movement of a US 
probe allows for acquisition of image volume in three dimensions (3D) at any time 
during surgery [6], [7]. Erdogan et al. reported 87% of agreement between iUS and post-
operative contrast enhanced MRI in detecting tumor residue in a prospective study of 
32 patients [12]. iUS is cheap and easily repeatable but acquisition is operator 
dependent, interpretation of the images requires training and experience and deep 
tumors cannot be identified due to low resolution [6], [7]. 
 
 Intraoperative functional mapping and monitoring are essential for safe excision 
of GBM when it is near to eloquent brain areas such as somatosensory, motor and 
language cortex with minimal risks for neurological deficits. While motor mapping can 
be performed in asleep or awake patients, for language mapping awake surgery is 
needed [13]. Using these functional methods, resection can be extended to the 
functional borders placed in the peritumoral tissue invaded by the tumor cells beyond 
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the anatomical borders [11]. 
 
 Intraoperative tissue fluorescence has the power to provide real-time 
information with no interference of brain shift while being still affordable. It demands 
microscopes equipped with appropriate filters to detect fluorescent light emission of 
specific agents. Fluorescence can be induced by: i) metabolic activity; ii) passive 
permeability; iii) targeted probes; iv) and autofluorescence [14]. 
5-aminolevulinic acid (5-ALA) as a fluorescent pro-agent represents the state-of-art for 
fluorescence guided surgery of GBM. It was approved in Europe in 2007 while in US in 
2017, and it is now used in over 40 countries [7]. 5-ALA is an endogenous metabolite 
converted to fluorescent protoporphyrin IX (PPIX), which chelates with iron in presence 
of enzyme ferrochelatase (FECH) to produce heme. Heme is then converted into 
bilirubin by heme oxygenase-1 (HO-1) [15]. In most of GBM cells, FECH enzyme is 
missing or has reduced activity resulting in the accumulation of PPIX into the tumor 
tissue. When excited with blue-violet light, PPIX emits a red fluorescence allowing for 
differentiation between tumor and healthy cells. 5-ALA derived fluorescence has been 
shown to be more sensitive compared to preoperative MRI contrast enhancement and 
positron emission tomography (PET) [16], [17]. Higher sensitivity enabled surgeons to 
achieve a double rate of complete resection and 6 months progression-free survival 
rates than patients who underwent conventional microsurgery under white light. 
Typically, 5-ALA is administered orally to the patients 4 h before the operation at a dose 
of 20 mg/kg body weight [18]. Nonetheless, this methodology faces several hurdles: i) 
low-grade gliomas do not respond to the administration; ii) fluorescence is not 
homogeneous in the periphery of the tumor and depends on the cell density; iii) false 
positive cases have been reported due to the presence of reactive astrocytes and 
macrophages [14], [19]–[22]; iv) sensitivity to prolonged exposure of light decreases the 
contrast; v) and penetration depth achieved with blue light is shallow [23]. Conversely, 
GBM cells do not show fluorescence depending on the EGFR activation and the presence 
of its constitutively active variant, EGFRvIII. Indeed, receptor activation has a 
downstream effect on HO-1, whose activity results in accelerated heme depletion with 
consequent shift of enzymatic activity in favor of increased PPIX metabolism by FECH 
(Figure 1) [15]. In attempt to reduce fluorescence variability in GBM cell lines and to 
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achieve a more objective fluorescence visualization, recent findings have shown the 
possibility to increase the signal pharmacologically and to quantify the concentration of 
PPIX by mean a microscope (Qp9-microscope) specially built for this purpose [24]. 
 
Figure 1. 5-ALA metabolism and its connection with EGFR activation in GBM cells. 5-ALA is metabolized 
into PPIX, which after excitation allows for visualization of the tumor as pink mass. Upon binding of the 
EGF, receptor activation promotes HO-1 activity, through the PI3K/AKT/NF-κB cascade, inducing the 
conversion of heme in bilirubin and the reduction of PPIX in the cells [15]. 
 
Fluorescein and indocyanine green (ICG) are responsible of passive permeability 
induced fluorescence. Accumulation follows the principle of the enhanced retention 
and permeability (EPR) effect therefore is not tumor specific. Fluorescein displays a 
yellow-green fluorescence visualized by the naked eye at high dose of 5-10 mg/kg body 
weight [7], [11]. Due to limited specificity and sensitivity concerns, surgeons risk to 
remove healthy tissue or to leave behind tumor tissue, respectively [25]. ICG stains 
tumoral and peritumoral blood flow and vascularization. The typical dose is 0.3 mg/kg 
body weight. It emits in the NIR region allowing for a deeper visualization in the tumoral 
tissue. Non-specific binding to proteins and rapid clearance (t1/2 ≤ 5 min) are the main 
drawbacks in the brain tumor surgery [7]. 
Next generation fluorophores contain targeted agents to address tumors. With high 
specificity and low toxicity, they have already reached the early clinical trials phase. 
Some examples are alkyl-phosphocholine analogues, chlorotoxin (TumorPaint), EGFR-
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targeted or αvβ3 integrin-targeted agents and phospholipids nanoparticles. All of them 
are usually conjugated to NIR fluorophores [14].  
 
 Implementation of Raman imaging as an adjunct technique for neurosurgical 
guidance has gained special focus due to its undoubtedly potential (Figure 2). First, it 
requires no need of either labeling or complex sample preparation; second, it is non-
invasive and non-disruptive causing no harm to the patient; third, high spatial 
resolution, sensitivity and selectivity enable a fast and real-time discrimination between 
malignant and benign tissue even down to molecular level, preventing removal of 
normal tissue and minimizing the volume of residual tumor with a considerable positive 
impact on patient survival [26]. All these features make Raman imaging able to address 
the main current clinical matter: the lack of intraoperative methods with sufficient or 
clinically relevant sensitivity and specificity for an objective identification of the tumor 
margins and the microscopic infiltrating foci [27].  
The feasibility of Raman imaging for neurosurgical guidance has been explored by 
several groups. It was used to delineate tumor tissue, both ex and in vivo, in a human 
GBM xenograft mouse model and in human brain tumor surgical specimens resulting in 
a near perfect agreement between Raman detection of tumor infiltration and 
histological staining [28]. Likewise, it was employed to distinguish GBM from gray 
matter and necrosis with 99.6 and 97.8% accuracy in the training set and validation 
cohorts, respectively [29]. A miniaturized handheld fiber optic probe was adopted to 
discriminate cancer cells from the surrounding non-cancerous tissue due to their 
intrinsic fingerprint spectra. Real-time information were obtained in vivo in 17 patients 
during brain tumor resection with at least 90% accuracy and resolution of as few as 17 
cancer cells/0.0625 mm2, overcoming 5-ALA induced fluorescence that mainly revealed 
bulk tumors [30]. 
Beside label free detection, nanoparticles based labeling has been introduced to 
counteract the intrinsically weak signal of Raman spectroscopy making it a much more 
powerful tool. Gold core-satellite assembly nanoparticles were used to clearly 
distinguish fixed or living GBM from normal cells with a Raman intensity 5 to 15 times 
higher for GBM [23]. Similarly, integrin-targeted surface enhanced resonance Raman 
spectroscopy (SERRS) nanoparticles were shown to depict the true tumoral microscopic 
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extent in vivo in a GBM mouse model with a detection sensitivity in the femtomolar 
range [31]. The handheld fiber optic probe described above was adopted in conjugation 
with silica SERS nanoparticles in a GBM mouse model reducing the acquisition time from 
10-20 to 0.1 s. Furthermore, SERS nanoparticles suffer from negligible loss in signal over 
time. Compared to the instrumentation commonly present in the operation room, the 
handheld scanner has the advantage of being easy to handle and flexible allowing to 
investigate the tumor resection bed from any directions [5]. 
In attempt to improve surgical outcomes, multimodal brain imaging has been assumed. 
Triple-modality nanoparticles were designed to combine MRI, photoacoustic and 
Raman imaging and the key factors of each of these techniques: localization of brain 
tumor and delineation of its margins before and during the operation using MRI; high 
spatial resolution and 3D imaging using photoacoustic; high-sensitivity, specificity and 
surface resolution of tumor margins using Raman [10]. pH-responsive nanoparticles 
were designed for guiding brain tumor visualization and resection by sensing acidic 
tumor microenvironments via simultaneous activation of MRI and SERRS. The acidic 
environment, typical of solid tumor, promoted nanoparticles self-assembly while those 
diffusing in the normal brain, at neutral pH environment, were washed away. Since 
extracellular acidification is a hallmark of all solid tumors, this strategy does not depend 
on tumor genotypes or phenotypes [32]. 
Figure 2. Schematic representation of Raman guided surgery. A) The main tumor mass is resected (black 
shadow). B) Raman fingerprint spectrum allows to identify and to remove residual cancer cells and 
infiltrating foci on the edges and beyond the resection cavity. C) Complete removal of tumor mass is 
achieved. 
 
Engineered nanoparticles, together with Raman spectroscopy, have the potential to 
revolutionize the diagnosis and treatment of brain tumors. A deep and full 
characterization of their surface functionalization is required since it affects their 
performance in terms of colloidal stability and their interaction with cells in terms of 
A B C 
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sedimentation, dissolution, formation of a protein corona and binding specificity. The 
most common approach to functionalize nanoparticles as SERS tags is illustrated in 
figure 3. 
Figure 3. Schematic structure of a SERS tag. The Raman reporter molecules encase the nanoparticle. A 
protective shell made of a polymer increases the stability and provides the surface to attach the 
antibodies. 
 
A nanoparticle is surrounded by a layer of Raman reporter (a Raman active molecule), 
followed by a protective shell. To target specifically SERS tags to tumor, antibodies or 
other affinities ligands are used [33]. 
Non-specific binding can represent a bottleneck in improving detection sensitivity and 
tagging specificity. Nanoparticles tend to be “sticky” and to bind non-specifically to the 
cellular membrane causing high levels of background that degrades the signal-to-noise 
ratio and produces false positives [26], [34], [35]. This effect highlights the importance 
of controlling surface modification to find an optimum balance between inert and 
receptor specific active functionalities in order to achieve maximum SERS intensity and 
minimize nanoparticle non-specific interactions [35]. 
In this thesis, SERS based imaging is the technique that has been investigated for 
improved intraoperative visualization of GBM cells. Hence, elucidation of the optical 
methodology behind this technique as well as of its evolution over the time is reported 
in the upcoming section. 
 
 
 
 
Nanoparticle Raman reporter Antibody Protecting shell 
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1.2 Raman spectroscopy 
Raman spectroscopy is an optical methodology measuring the frequency shift of the 
inelastic scattering of light. When a monochromatic laser beam hits the molecule, 
energy is exchanged between intramolecular vibrations bonds and photons producing 
a change in the bond's vibrational state. Most of the scattered photons has unaltered 
energy (elastic or Rayleigh scattering). Minor part of scattered photons experiences a 
change of energy (inelastic or Raman scattering). Gain of energy is termed anti-Stokes, 
whereas loss of energy is termed Stokes (Figure 4) [36]. 
 
Figure 4. Jablonski diagram representing quantum energy transitions for Rayleigh and Raman 
scattering. After interaction with the incident photon, the molecule is excited to a virtual energy state. If 
the energy of the emitted photon, when the molecule relaxes to a lower energy level, is equal to that of 
the incident photon, the process is elastic and it is known as Rayleigh scattering. If the energy is lower or 
higher, the process is inelastic and it is known as Stokes or Anti-Stokes scattering, respectively [37]. 
 
This change in the photon's energy is known as ‘Raman shift’. Collision of photons with 
different biochemical bonds within the tissue generates several Raman shifts, which 
taken together generate the ‘Raman spectrum’. The Raman spectrum gives fingerprint 
information that resolve the molecular composition in cells or tissues providing a truly 
objective picture of the pathology. The intensity of Raman scattering is proportional to 
the magnitude of the change in the molecular polarization where polarizability results 
from the displacement of the electrons from the equilibrium position as a consequence 
of the molecular vibrations [36]. However, the weakness of spontaneous Raman 
scattering (for every 1-10 million photons bombarding a sample, only one will result in 
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Raman scattering) has hindered the spread of Raman spectroscopy until advanced 
instrumentation and enhancement Raman techniques have been discovered (Figure 5). 
 
Figure 5. Evolution of Raman spectroscopy. Raman spectroscopy timeline from its discovery to the most 
recent advanced techniques [38]. 
 
1.2.1 Evolution of Raman spectroscopy 
In resonance Raman scattering (RRS) the excitation wavelength is chosen to 
overlap with (or be very close to) an electronic transition. This typically means in an area 
of ultraviolet-visible (UV-Vis) absorption. Such overlap boosts the scattering efficiency 
by factors of 102-106. However, since the excitation falls in the UV-Vis region, 
fluorescence background represents a substantial problem [39]. 
 
Coherent anti-Stokes Raman scattering (CARS) uses three laser fields instead of 
the traditional single laser. They are a pump field at frequency of ωp, a Stokes field at ωS 
and a probe field at ωpr. When the energy difference of the pump and Stokes beams 
(ωp−ωS) equals the frequency of a molecular vibration mode (Ω), the Raman resonance 
occurs. This resonance is then probed by the third field at ωpr generating an anti-Stokes 
field at (ωp−ωS+ωpr) [40]. The Raman active mode of interest is the only extremely strong 
peak in the Raman spectrum providing a speed advantage over spontaneous Raman. 
 
Like CARS, stimulated Raman scattering (SRS) is based on two incident photons 
but produces a signal at the same frequency than the excitation wavelength. Thus, SRS 
offers a linear dependence on concentration and shows identical spectra to 
spontaneous Raman with no interference complications from the non-resonance 
background like in CARS [41]. 
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Tip enhanced Raman spectroscopy (TERS) combines the spatial resolution of 
atomic force microscopy with the chemical information of Raman spectroscopy. An 
excitation laser beam is pointed on the apex of a metallic coated tip creating a confined 
and enhanced electromagnetic field. Sample, positioned at nanometer distance from 
the tip, experiences this enhancement leading to an increased Raman scattering [41]. 
 
Surface enhanced hyper Raman scattering (SEHRS) is the two-photon excited 
analogue of SERS (see next paragraph). SEHRS allows to acquire complementary 
spectroscopic information for improved understanding of molecule–nanostructure 
interactions and to probe molecules at lower concentrations due to higher sensitivity 
[42]. 
 
SERS is a surface sensitive technique that results in the enhancement of Raman 
scattering when molecule is absorbed on a metal surface allowing for its highly sensitive 
structural detection at low concentrations [41]. Given the importance of this technique 
in this work, the concepts judged important for a clear understanding are emphasized 
below. 
  
1.2.2 Surface enhanced Raman spectroscopy 
1.2.2.1 Localized surface plasmon resonance 
SERS enhancement comes mainly through the electromagnetic effect (Figure 6A), which 
takes advantage of a unique phenomenon on certain metal nanoparticles called 
localized SPR (LSPR). It is an optically excited electron wave resonance state that 
happens when the conductive band electrons at metallic nanostructure surface 
(localized surface plasmons) are excited by an external electromagnetic field (Figure 6B). 
The coherent oscillation of electrons generates a secondary electromagnetic field, 
which is added to the external electromagnetic field resulting in a signal intensity 
amplification. This makes nanoparticles highly sensitive transducers of small changes in 
the local refractive index. These changes become visible as a red shift of the absorption 
spectrum of the molecules upon coupling on the nanoparticles [43], [44]. The SERS 
enhancement factor is typically 106–108-fold [33]. 
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Figure 6. Illustration of SERS and LSPR. A) SERS consists in the enhancement of the Raman scattering 
when the analyte is attached or close to the metal surface (position 2). The analyte undergoes the highest 
electromagnetic field in the ‘hot spot’ where the metal particles are close (position 3). The further the 
analyte, the weaker the electromagnetic field (position 1) [adapted from 45]. B) SERS enhancement is 
attributable to the LSPR effect generated from the collective oscillation of electrons in response to an 
external electric field [46]. 
 
A smaller contribution to the enhancement is instead given from a charge transfer effect 
between the absorbed molecules with appropriate acceptor or donor orbitals and the 
metal substrate. This process is also known as first layer effect because the molecules 
directly in contact with the surface of the nanoparticles mainly contribute to chemical 
effect and exhibit a stronger enhancement in comparison to the adjacent layers [43], 
[44]. 
 
1.2.2.2 Substrates for SERS 
Good SERS substrates are rough electrodes or colloidal suspensions made of gold, silver 
or copper. They are strongly wavelength-dependent meaning that exhibit a good 
enhancement in a limited excitation wavelength range. Most SERS substrates are 
designed to operate with visible/NIR excitation (400-1’000 nm), which is the typical 
range of interest for molecular Raman scattering experiments [36]. Silver produces the 
highest enhancement factor because interband transitions fall in the UV range leading 
to reduce absorption in the visible or NIR range. Conversely, in case of gold and copper, 
interband transitions fall in the visible range reducing SERS amplification [47]. 
 
1.2.2.3 Intrinsic and extrinsic detection methods 
Two detection methods can be distinguished: intrinsic and extrinsic. Intrinsic SERS 
targets the molecule of interest directly supplying structural information useful to 
cv 
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identify even small difference between similar samples. However, the targeted 
molecule needs to be Raman active and its concentration high enough to be detected. 
Instead, extrinsic SERS detects the targeted molecule indirectly because it marks a 
Raman reporter. This detection method requires further functionalization in order to 
target the molecule of interest [33]. 
 
1.2.2.4 Influence of chemico-physical properties of nanoparticles on SERS 
For optimized SERS enhancement, LSPR position can be tuned due to its dependence 
mainly on the size, shape and aggregation state of nanoparticles. Increased size causes 
a red shift of LSPR and higher SERS intensity because of the presence of more available 
electrons. However, this is valid until nanoparticles size approaches the scale of the 
excitation wavelength: for these particles the enhancement diminishes due to the 
radiation damping effect. When particles are too small, the effective conductivity and 
light scattering properties diminish [48], [49]. In addition to the position, the 
morphology also changes the number of LSPR peaks accordingly to the way in which 
nanoparticles can be polarized. While nanospheres present only one peak, nanorods 
have two peaks, once longitudinal and the other one transversal. The highest SERS 
enhancement up to 1014-fold is usually recorded in localized areas known as ‘hot spots’. 
They can be either gaps smaller than 2 nm, formed when two or more nanoparticles 
cluster, or sharp corners and tips in anisotropic nanoparticles. In the latter case, the 
lightning rod effect causes the dipolar field to be focused at the tip allowing the 
nanoparticles to behave as an optical antenna. The analyte does not need to be in direct 
contact with the surface of nanoparticles. Indeed, it has been reported that SERS 
enhancement extends to a distance of 10 nm but diminishes following the distance 
dependence: I = (1 + r/a)-10, where I is the SERS intensity, a is the radius of the 
nanoparticle and r is the distance of the analyte from the metallic surface [43], [50]. In 
case of extrinsic SERS, it is worth mentioning that the selection of both the Raman 
reporter and the protective coating layer plays a role in the final electromagnetic 
enhancement. The Raman reporter must: i) be polarizable to be Raman active; ii) be 
photostable for prolonged exposure to the laser with no significant decay of the signal; 
iii) and have high binding affinity to elicit chemical enhancement mechanism. Molecules 
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with sulfur or amine, such as DTTC, R6G, crystal violet and some small molecules 
containing thiol such as p-BDT, are preferred because they strongly bind to gold via the 
gold thiolate bond [51]–[54]. A study comparing two organic chromophores, malachite 
green (MG) and its isothiocyanate derivative (MGITC), showed that the enhancement 
factor of MGITC was ∼200-fold higher than MG under the same experimental conditions 
[55]. Fluorescent dyes and other chromophores are often used because they have large 
Raman scattering cross sections. Raman reporters can also match the excitation 
wavelength inducing SERRS and further enhance the Raman signal [31]. Beside existing 
Raman reporters, molecules can be specially synthesized for improving their binding to 
gold. For instance, lipoic acid was added to a triphenylmethine dye as a linker to 
covalently attach the reporter on gold colloid [56]. As alternative, molecules positively 
charged can be coupled to negatively charged nanoparticles although they can be prone 
to desorption. 
About the SERS protective coating, it should not interfere with the detection of the 
Raman reporter and it should not cause its displacement [33]. The protective shells 
consist of mono or multilayers of polyelectrolytes or silica even though the latter was 
reported to cause adsorption competition with Raman reporter or reduction of SERS 
signal up to 60% [5], [10], [57]–[60]. PEG is often preferred because it prevents reporter 
leaching and nanoparticles aggregation [32], [53], [56]. Most important, PEG 
significantly improves circulation time of nanoparticles, a necessary requisite for GBM 
imaging as discussed in depth shortly [59], [61]. 
 
1.2.2.5 Chemico-physical properties of nanoparticles for SERS based imaging of 
glioblastoma 
Of all nanostructures, application of GNPs as SERS tags for SERS guided surgery is based 
on three major advantages, i.e., remarkable biocompatibility, negligible toxicity and 
amenability to functionalization [62]. Formulation of an ideal molecular imaging agent 
requires satisfying some criteria. It must: i) avoid opsonization and clearance by the 
reticuloendothelial system (RES); ii) be selectively delivered to the brain and be able to 
cross the BBB; iii) be extensively retained in the tumor so that a single injection is enough 
for preoperative planning and intraoperative resection; iv) emit a signal stable for the 
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whole duration of the surgery that lasts in average 4 h; v) and be active in the NIR region 
known as a ‘clear window’ for optical imaging because the blood and water absorption 
spectra are minimal and the depth of penetration is higher [31], [62], [53]. All these 
features can be tailored by controlling the physico-chemical properties of GNPs. Both 
size and shape contribute to clearance, in vivo biodistribution, strength of adhesion and 
internalization rate in the cells and SERS enhancement. Particles of 60-80 nm are the 
most efficient for SERS in the NIR region [53]. GNPs smaller than 5 nm are rapidly 
eliminated through renal clearance [63], [64]. GNPs bigger than 200 nm are usually 
prone to opsonization. Proteins of the immune system, known as opsonins, are 
absorbed on the GNPs surface so that monocytes and macrophages can promptly 
recognize, remove from the blood stream and bring the GNPs to the liver, spleen and 
bone marrow [63]. Considering that blood and liver account for the accumulation of 
approximately 70-80% of the injected GNPs, the gold bioavailability in the brain is 
limited for imaging [65]. Different strategies can be applied to improve circulation time. 
Neutral surface charge reduces recognition by the RES but, at the same time, makes 
GNPs susceptible to aggregation. Positive or negative charge increases macrophages 
uptake but improves particles stability and their interaction with the cells. Alternatively, 
addition of PEG can create an extra hydration layer resulting in a ‘stealth’ behavior and 
circumventing the RES [61], [63].  
 
1.2.2.6 Passive and active targeting of glioblastoma 
Passive permeation of PEGylated GNPs within transport-permissive brain 
microvasculature is a size-dependent process with respect to both GNPs core size as 
well as PEG chain length [66]. Approximatively 0.3% of 10 nm GNPs was shown to pass 
through the BBB after 24 h from the injection and this percentage dropped as soon as 
size increased [65]. However, accumulation of GNPs with a final size of 120 nm was 
successfully reported in GBM bearing mouse [5], [10].  
To improve the passage of GNPs through the BBB and to enrich the amount of gold in 
the brain, an effective strategy is the active targeting. It relies on two kinds of transports: 
absorption mediated transport (AMT) and receptor mediated transcytosis (RMT). AMT 
uses cation proteins or cell-penetrating peptides to trigger the interaction between the 
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GNPs and the negatively charged membrane of brain capillary endothelial cells. 
Nevertheless, it is a non-specific process leading to accumulation of GNPs in non-
targeted or non-diseased area. For increased targeting specificity, RMT appeals for 
immobilization of target receptor specific biomolecules on the GNPs surface. Targeting 
moieties commonly used for GBM are: i) proteins such as transferrin, fibroblast growth 
factor and low-density lipoprotein-receptor-related protein-1; ii) peptides such as trans-
activating transcriptor and RGDyK; iii) and antibodies against transferrin receptors or 
EGFR [61], [67]. Antibodies can be employed in their native form, as single-chain variable 
fragments or affibodies [53], [68]. Conjugation of these ligands allows for a remarkably 
more intense and lasting tumor enhancement with respect to the unconjugated 
counterpart. 
Among the different brain malignant tumor types, GBM was chosen because this tumor 
is considered the most challenging to resect due to the diffuse pattern of tumor spread. 
Detailed definition, classification, diagnosis and strategies of treatment are described in 
the following section.  
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1.3 Glioblastoma 
Gliomas account for the 80% of malignant brain tumors arising from glial cells such as 
astrocytes, oligodendrogliomas or ependymal cells [69]. According to the 2016 World 
Health Organization (WHO) classification, which takes into account the molecular 
parameters in addition to the histopathologic appearance, two main categories can be 
defined: i) diffuse gliomas whose main feature is a highly infiltrative pattern in the 
central nervous system parenchyma; ii) and more circumscribed gliomas of which 
astrocytoma and ependymomas are the most representative [70]. Constituting more 
than 50% of all gliomas, grade IV GBM is the most frequent tumor belonging to former 
category (Figure 7) [69], [71]. 
Figure 7. Statistical distribution of gliomas and classification of GBM according to the 2016 WHO.  
 
GBM can be primary or secondary depending on whether it appears de novo or it 
progresses from a lower WHO grade tumor, respectively. Primary GBM is more common 
in men with a median age of 62 and only 8.8% is diagnosed in children. Conversely, 
secondary GBM affects mainly women with a median age of 45 [71]. 
Even though GBM was thought to be characterized by a heterogeneous histological 
appearance only, whence the name multiforme, newly acquired knowledge regarding 
molecular abnormalities or genetic alterations has led to the definition of specific GBM 
types. Based on the presence or absence of isocitrate dehydrogenase (IDH) gene 
mutations, it is possible to distinguish: i) GBM: IDH-wildtype; ii) GBM: IDH-mutant; iii) 
and GBM: NOS (not otherwise specified). Primary GBM is IDH-wildtype and it is further 
discriminated in giant cells GBM, gliosarcoma and epithelioid GBM. IDH catalyzes the 
conversion of isocitrate into α-ketoglutarate within the citric acid cycle. Present in 
secondary GBM, IDH mutation causes a hypermethylation phenotype, changes in 
cellular metabolism and responses to hypoxic and oxidative stress. The third category, 
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GBM: NOS, encompasses all kind of GBM lacking of specific information to be assigned 
to one of the previous classes [11]. 
 
1.3.1 Etiology, incidence and prognosis 
Its formation cannot be prevented since the exact causes remain elusive although 
exposure to ionizing radiation might be associated with an increased risk of glioma [69], 
[71]. It has a global incidence of two to three per 100.000 adults per year and a median 
survival rate not longer than 15 months [11], [71]. This disheartening prognosis makes 
GBM the most challenging and lethal brain tumor worldwide. 
 
1.3.2 Unique challenging features  
GBM consists of a mass with a central necrotic core surrounded by thick and irregular 
margins. Abnormal accumulation of fluid (infiltrative edema) around the tumor causes 
further brain swelling exacerbating the symptoms (Figure 8A). The following features 
make the clinical management arduous and challenging: 
- Localization: GBM is usually localized in the supratentorial compartment. Lesions 
have origin in the deep white matter to infiltrate often into the cortex. In the 
worst case, it can extend across the corpus callosum to the opposite hemisphere 
assuming the characteristic butterfly shape (Figure 8B). GBM rarely forms 
metastases outside of the central nervous system [71]; 
- Highly infiltrative pattern: cells invading individually or in small groups the 
normal brain parenchyma are hallmarks of GBM. Invasion occurs preferentially 
along the existing brain structures but even through the blood vessels and the 
white matter. Infiltrating tumor cells usually form deeply seated structures 
beyond the margins for maximal resection eluding the current visualization 
technique and giving rise to tumor relapse [68]; 
- Resistance or limited response to conventional therapies: GBM cells are not only 
resistant to chemotherapy and ionizing radiation, but those conditions prompt 
them to invasive behaviors [72].  
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Figure 8. Illustration of GBM structure. A) T1 and T2-weighted images of GBM and a schematic 
representation of GBM structure: a necrotic core with asymmetric margins is surrounded by edema [73]. 
B) MRI image of a bifrontal lesion across the corpus callosum with the butterfly shape [74]. 
 
1.3.3 Aberrations of epidermal growth factor receptor  
The most common alteration concerns the EGFR. EGFR belongs to the ErbB receptors 
family with tyrosine-kinase activity. It is a single chain transmembrane protein of 170 
kDa made up of three domains: i) an extracellular ligand-binding domain; ii) a 
hydrophobic transmembrane domain; iii) and a cytoplasmic domain with tyrosine kinase 
activity (Figure 9). The binding of the ligand to the ectodomain promotes the formation 
of transient homo or heterodimers and autophosphorylation of tyrosine residues within 
the carboxy terminal tail of the receptors. This recruits several cytoplasmic proteins, 
which initiate an intracellular signaling via several pathways leading to cell proliferation, 
survival, apoptosis, invasion and migration [75]. These pathways include the 
phosphoinositide 3-kinase, mitogen-activated protein kinase, signal transducer and 
activator of transcription 3 and Src family kinases [76]. 
Dysregulated EGFR signaling is a frequent hallmark that leads to a more aggressive GBM 
phenotype. This can be due to mechanisms such as EGFR overexpression at the cell 
membrane, enhanced autocrine activation or EGFR mutation and malfunction in 
receptor degradation. Occurring in almost 60% of primary GBM, while only in 10% of 
secondary GBM, EGFR overexpression is often a consequence of EGFR focal 
amplification at 7p12 or mutation. Approximately 50% of GBM overexpressing EGFR 
also shows concomitant expression of its truncated yet constitutively active form: 
EGFRvIII [76], [77]. EGFRvIII is a tumor specific mutation arising from an in-frame 
B A 
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deletion of exons 2–7 of the coding sequence that results in a shorter extracellular 
domain (Figure 9). EGFRvIII has a molecular mass of approximately 145 kDa [78]. Due to 
low level of autophosphorylation, receptor internalization is defective causing a longer 
presence at the cell surface and amplified mitogenic effects [79]. EGFRvIII expression 
has been associated with a dismal prognosis since GBM becomes resilient to therapies 
[76]. 
 
 
Figure 9. Schematic representation of EGFR wild type and EGFRvIII. EGFR consists of three domains: 
extracellular with the ligand binding site, transmembrane and intracellular. EGFRvIII lacks amino acids 6–
273 and presents a new glycine residue between amino acids 5 and 274. This deletion makes the receptor 
constitutively active and ligand-independent [80].  
 
1.3.4 Diagnosis 
Depending on the part of the brain where the GBM initiates, symptoms may vary from 
non-specific headaches to specific neurological deficits and disturbances such as: 
- Changes in mood and in ability to think; 
- Changes in sensory and memory issues; 
- Speech difficulty; 
- Seizures [11], [3].  
In addition to a neurological exam, the diagnosis is refined with imaging evaluation 
through MRI, PET and computerized tomography (CT) scan. CT is a fast and inexpensive 
method to supply initial data but MRI, with and without gadolinium contrast media, is 
usually preferred due to higher accuracy in sense of extension and specificity. Instead, 
PET uses biochemically active molecules labeled with radiotracers such as the glucose 
analog 18F-fluorodeoxyglucose to provide metabolic information of the tumor. 
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However, to achieve a correct diagnosis, histological assessments of sample obtained 
either by biopsy or resection should be performed [11]. 
 
1.3.5 Treatment 
First line of treatment of GBM is surgery followed by radiotherapy and chemotherapy. 
However, when lesion is too extended or close to sensitive areas, biopsy could be 
preferred since it carries fewer risks compared to the complete resection [81]. 
 
As stated above, surgery still remains the state-of-art treatment in GBM 
management. Increasing the extent of resection to a minimum of 70% of the initial 
tumor volume has been associated to a more favorable prognosis with a nearly 5-
months or greater than 40% increase in survival [82], [83]. Nonetheless, complete 
resection is achieved in fewer than 20% of cases [18]. 
 
Radiotherapy uses external high-energy beams, such as X-rays or protons, to kill 
or slow the growth of tumor cells. Specialized delivery systems direct radiations at the 
site of the tumor while minimizing the radiation dose to the surrounding brain. Although 
radiotherapy hits even the healthy cells, by the time the next treatment is given, most 
of them can repair the damage. This process is repeated for a total of 10 to 30 
treatments, usually given once a day, 5 days a week [84]. 
 
Chemotherapy is based on the use of Temozolomide (TMZ) or Lomustine (also 
referred as CCNU). They are alkylating agents that act by introducing a DNA mismatch 
in the replication cycle leading to cell death [1]. A daily dose of 150 to 200 mg/m2 of 
body-surface area is administered for 5 days every 28 days. Concomitant treatment with 
radiotherapy plus TMZ has shown to improve survival [85]. Common side effects arising 
from both types of treatments are fatigue, nausea, swelling, infertility and stroke [86].  
 
Recently introduced, tumor treating field (TTF) is a new technology that relies on 
the application of a low intensity, intermediate frequency and alternating electric field 
to inhibit cell mitosis. TTF restrains DNA damage repair, impairs cellular migration and 
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invasion and upregulates autophagy [87]. The use of TTF together with TMZ has shown 
to improve progression-free survival and overall survival [88].  
 
Novel approaches are under investigation such as vaccines, angiogenesis or small 
molecule tyrosine kinase inhibitors, monoclonal antibodies and RNA-based agents. 
Being a signature of GBM, it is not surprising that EGFR has been frequently chosen as 
first target of therapy. 
 
So-called small molecules tyrosine kinase inhibitors such as Gefitinib (Iressa®) 
and Erlotinib (Tarceva®) interfere with tyrosine kinase activity of the receptor thus 
altering the signal transduction cascade. None of these molecules has been approved 
for GBM due to unacceptable side effects, limited efficacy or difficult brain penetrance 
[79]. 
 
Monoclonal antibodies usually prevent the binding of the cognate ligand to the 
relative receptor. Bevacizumab (Avastin®) targets the vascular endothelial growth factor 
receptor and blocks the generation of new tumor-associated blood vessels [1], [2]. It is 
clinically used only for recurrent disease and symptoms alleviation. Cetuximab 
(Erbitux®) acts on the EGFR as an antibody-blocking with no receptor activation. It is also 
believed to induce receptor internalization and destruction [79]. Monoclonal antibody, 
mAb806, has been engineered for targeting the EGFRvIII. It recognizes a region usually 
hidden in EGFR impairing receptor autophosphorylation. Recent studies have shown 
that different mutations of EGFR cause conformational changes making the hidden 
region accessible to the antibody [89].  
 
Receptor inhibition can be even achieved at the transcription or translation level 
by mean antisense RNA, RNA interference and ribozymes. Pre-clinical outcomes in this 
field are very promising [1], [79]. 
 
Feasibility and safety of so-called chimeric antigen receptor-T cells have been 
shown in the treatment of GBM. Patients own T cells are modified in the lab to recognize 
the EGFRvIII. After recognition, primary T-cell activation occurs and leads to cytokines 
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release, degranulation and T-cell proliferation [90]. 
 
One of the reasons why GBM is so aggressive and difficult to treat is the presence of the 
BBB, which precludes access of a wide variety of therapeutic or imaging agents to the 
tumor [91]. 
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1.4 The blood brain barrier 
The BBB is a highly selective semipermeable interface between the blood circulation 
and the central nervous system at the microvasculature level, whose main task is to 
protect against circulating harmful substances or pathogens that could cause brain 
infections, while allowing vital nutrients to reach the brain [92]. The first line of this 
barrier consists of a monolayer of endothelial cells delimiting the capillary lumen. It is 
characterized by tight cell-cell junctions (TJs) and a lack of fenestrations. The presence 
of TJs reduces the paracellular movement of substances and contributes to the high 
transendothelial electrical resistance (TEER) of >1,500 Ω*cm2 [92]. However, 
transcellular transport is still allowed due to the presence of several classes of nutrient 
transporters and efflux pumps (Figure 10) [93]. 
 
Figure 10. Transport system at the BBB. Despite TJs reduce the paracellular transport, the passage of 
substances is possible through transcellular pathways. Solute carrier family allows the passive transport 
of polar nutrients such as glucose and amino acids. Efflux pumps of the ATP-binding cassette superfamily 
pump out potentially toxic substances; while larger molecules and proteins such as transferrin, insulin 
and IgG are delivered through RMT or AMT [93]. 
 
Pericytes stick to the endothelial cells on the abluminal side. Both cell types are enclosed 
by the basal lamina, a membrane of 30 to 40 nm contiguous with the plasma membrane 
of astrocyte end-feet (Figure 11A). It is composed of collagen type IV, heparin sulfate 
proteoglycans, laminin, fibronectin and other extracellular matrix proteins. Main 
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components of the TJs are transmembrane proteins such as junctional adhesion 
molecules, occludins and claudins. In the cytoplasm, there are several accessory 
proteins associated with them. The most known are the zonula occludens (ZO) proteins, 
which belong to the membrane-associated guanylate kinase family [94]. When tumor 
occurs, BBB integrity is damaged due to extensive abnormal angiogenesis and loss of TJs 
with the consequent formation of large gaps. These gaps may measure as much as 0.5 
to 1 nm, although smaller gaps are more common. Together, they open a direct 
communication between the vascular lumen and the basement membrane or directly 
to the brain parenchyma. Indeed, in the most abnormal vessels, the basal lamina is 
absent or, if present, is a thin and irregular line. In addition, the glial sheath is 
represented only by rare tumor cells close to the basal lamina with large areas of the 
basal lamina in direct continuity with the extracellular space (Figure 11B) [95]. This 
disruption enables on one hand the spread of tumor cells through the blood with 
formation of metastasis, on the other hand the increased extravasation of agents from 
the blood into tumor tissue. Such behavior is the base of EPR effect [96]. However, BBB 
disruption is not uniform and tumors often contain subregions with intact and especially 
robust BBB (or blood tumor barrier, BTB), leading to cancer cell treatment resistance.  
 
Figure 11. Schematic illustration of BBB and BTB. The BBB is made of three cell types: brain capillary 
endothelial cells, pericytes and astrocytes. Endothelial cells are tightly in contact to prevent paracellular 
transport. In case of tumor, the barrier undergoes structural changes: the major one concerns the loss of 
TJs to leave place to fenestrations making the barrier leaky [97]. 
 
1.4.1 Strategies for overcoming the impermeability of the BBB 
To date, different approaches have been adopted to temporally disrupt or bypass the 
Blood brain barrier Blood tumor barrier 
Basal lamina 
Astrocyte foot 
Pericyte 
TJ 
Pinocytic 
vessicle 
Fenestration 
Tumor cell 
 35 
BBB allowing oversized GNPs to enter the tumor.  
 
Osmotic agents such as mannitol or bradykinin analogues are commonly used 
but result in widespread BBB disruption with the potential for deleterious consequences 
[98]. 
 
 Convection-enhanced delivery can confine the lesion to a specific area placing 
several catheters directly within or around the tumor mass. A positive pressure is 
applied pushing the infusate into the extracellular fluid without inducing systemic 
toxicity [99]. Major pitfalls are related to safety concerns of open surgery and leakage 
of the infusate or reflux along the catheter tract [100]. 
 
Focused ultrasound (FUS) with lipid-encased gas-filled microbubbles increases 
permeability in a focal and reversible manner. When low frequency US waves are 
applied transcranially, the intravascular microbubbles oscillate in the acoustic field 
eliciting mechanical forces against the TJs of the endothelial cells that line the vessel 
wall [99]. FUS is safe and minimally invasive. The ensuing BBB disruption lasts at most 
for approximately 4 hours [98]. 
 
The disruption of the BBB requires that GNPs cross the BBB only in pre-treated areas, 
implying a priori knowledge of tumor invasion boundaries. This is counterintuitive since 
using diagnostic GNPs aims at achieving an ultra-sensitive detection of tumor edges at 
a macroscopic and microscopic level [62].  
 
1.4.2 In vitro models of the BBB 
Investigation of the ability of GNPs to cross the BBB and to reach the brain is essential 
to predict the performance of GNPs in a clinical context. Besides in silico and in vivo 
models, in vitro BBB models offer a valid tool to study different aspects of the BBB 
functions and interactions with potential drug candidates (such as uptake, mechanisms 
of transports and cytotoxicity). So far, transwell models or microfluidic devices are 
available. Availability of human primary brain material is limited and restricted to biopsy 
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or autopsy material, thus endothelial cell lines isolated from human or animal sources 
are used. Despite the endothelial cells are not the only component of the BBB, they are 
believed to mainly contribute to the formation of the barrier. They can be cultured alone 
or together with astrocytes or pericytes. 
The human brain endothelial cell line, hCMEC/D3, has been used to establish a well 
characterized in vitro BBB model [101]. This cell line displays a stable and physiologically 
normal endothelial phenotype and keeps most of the structures and biochemical 
properties of brain endothelium in vivo [102]. It is worth mentioning that hCMEC/D3 
cell line is characterized by low TEER levels ranging from 5 to 50 *cm2 and reduced 
expression of ZO-1 and claudin-5 when cells are grown to confluence on transwell 
inserts [103]. Nevertheless, cell monolayer displays a highly restricted permeability to 
standard drugs in good correlation with in vivo permeability values from brain perfusion 
studies, confirming its suitability for transendothelial permeability analyses [102]. 
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2. Motivation and aims of the thesis 
 
 
 
Complete resection of contrast enhancing malignant brain tumors is achieved in 
less than 20% of cases. This is due to the difficulty to sharply delineate tumor margins 
and to identify infiltrative cancer cells specially in case of GBM [5], [18]. Therefore, 
improving intraoperative visualization of cancer cells is the motivation that gives rise to 
this project. SERS based imaging of GBM is promising to fulfil most of the requirements 
that current intraoperative guidance techniques have not met yet. A handheld Raman 
scanner, easy to use and able to interrogate the resection bed from any directions, is 
currently under clinical trial [5]. GNPs, if properly engineered, are able to cross the BBB 
and their detection in the NIR window counters the autofluorescence and increases the 
penetration depth [5], [10], [53]. In addition, SERS signal, when no fluorescent Raman 
reporters are used, is photo-stable ensuring a strong detection for the whole-time frame 
of the surgical operation [23]. However, successful visualization of GBM cells strongly 
depends on formulation of GNPs with increased sensitivity and binding affinity. To 
accomplish this task, surface functionalization of GNPs must consider a balance 
between inert and receptor specific active surface molecules. Indeed, we hypothesize 
that final performance of SERS tags, in terms of maximal colloidal stability and SERS 
signal, highest receptor binding affinity and lowest non-specific binding, depends on the 
proper mixture of Raman reporter, inert protective layer of PEG and antibody (Figure 
1). 
In order to establish a sensitive and selective intraoperative guidance technology for 
GBM detection, this thesis includes: 
i) the preparation of SERS tags with several ratios of Raman reporter, inert protective 
PEG coating and antibody; 
ii) the investigation of how these ratios affect colloidal stability, cellular binding 
specificity in vitro on cultured human GBM cell lines and Raman sensitivity; 
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iii) the determination of the optimum incubation time, concentration and surface 
chemistry to achieve the maximum SERS intensity while minimizing GNPs aggregation 
and non-specific binding; 
iv) the modulation of SERS tags surface charge to reduce non-specific binding; 
v) the establishment of an in vitro BBB model for evaluating the ability of SERS tags to 
cross the BBB before further in vivo investigation. 
 
Figure 1. Influence of surface chemistry on SERS tags performance. The mixture of Raman reporter and 
PEG acts on gold colloidal stability, Raman signal intensity, cellular receptor binding affinity, non-specific 
binding and scan speed. Full PEG surface coverage is supposed to elicit a higher binding specificity and 
GNPs stability and to allow the conjugation of higher antibody concentrations. Conversely, full Raman 
reporter surface coverage is supposed to boost the Raman sensitivity reducing the acquisition time. 
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3. Results 
 
 
 
3.1 SERS tags preparation and characterization 
Tags for SERS based imaging of GBM were developed by coating 60 nm GNPs (Figure 1A) 
with 1,4-Benzendithiol (1,4-BDT) (Figure 1B) used as Raman reporter (Figure 1C). 
Unconjugated GNPs were then produced by sequentially backfilling remaining free 
spaces with first carboxy-PEG-thiol (cPEG) followed by methoxy-PEG-thiol (mPEG) to 
improve binding specificity and biocompatibility (Figure 1D). To target specifically GNPs 
towards tumor cells, antibodies against EGFR were covalently conjugated producing 
anti-EGFR GNPs (Figure 1E). 
Figure 1. Design of tags for SERS based imaging of GBM. A) Transmission electron microscopy picture of 
60 nm GNPs in citrate buffer. Image taken with EM 900 transmission electron microscope (Zeiss), 
acceleration voltage 50 kV. Scale bar 50 nm. B) Chemical structure of 1,4-BDT used as Raman reporter. C) 
The Raman reporter, 1,4-BDT, is immobilized on gold surface for maximal SERS sensitivity (1,4-BDT GNP). 
D) PEG is used to create an inert shell for improved stability and to prevent non-specific binding 
(unconjugated GNP). E) Anti-EGFR antibodies are then conjugated for active targeting (anti-EGFR GNP). 
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Several surface coverage percentages of Raman reporter and PEG were tested. 
Considering a perpendicular orientation of Raman reporter with a footprint of approx. 
0.09 nm2, and a mushroom configuration of PEG with a footprint of 0.35 nm2, the 
theoretical number of molecules required for a 100% surface coverage of the gold area 
of 11’304 nm2 was calculated for each ratio (Table 1). From now on, each chemistry ratio 
is reported in function of the Raman reporter surface coverage used. 
 
Raman 
reporter 
(µM) 
Raman 
reporter 
surface 
coverage (%) 
Raman 
reporter 
molecules 
cPEG 
molecules 
mPEG 
molecules 
Total PEG 
surface 
coverage (%) 
4 100 128'000 0 0 0 
2 50 64'000 5'000 11'000 50 
1 25 32'000 5'000 19'000 75 
0.4 10 12'800 5'000 24'000 90 
0 0 0 5'000 27'000 100 
 
Table 1. Theoretical calculation of molecules required to form a monolayer. Concentrations of Raman 
reporter and corresponding surface coverages or number of molecules are reported. Both cPEG and 
mPEG were used, thus the number of the respective molecules and the total PEG surface coverage are 
listed. 
 
3.1.1 Raman reporter coupling for SERS 
 
Figure 2. Optical and physical properties of 1,4-BDT GNPs. A) Absorption peak of GNPs coated with 
increasing 1,4-BDT surface coverages. UV-Vis extinction spectra acquired with Sinergy H1 microplate 
reader (BioTek Instrument, GmbH). B) Hydrodynamic size and negative zeta potential correlated to 
increasing 1,4-BDT surface coverages. Analysis done with Zetasizer ZS dynamic light scattering instrument 
(Malvern Panalytical Ltd, UK), T 25°C, pH 7, n=3, mean ± SD. 
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SERS tags were produced by coating GNPs with theoretically increasing surface 
coverages of 1,4-BDT, from 0 to 100%. 10-fold excess (10x 100%) Raman reporter was 
even tested to ensure the complete surface saturation. UV-Vis spectra were recorded 
as first and fast control of surface modification. LSPR, centered at 540 nm for bare GNPs, 
experienced a progressive red shift up to 5 nm with 10-fold excess Raman reporter, as 
a result of the increased local refractive index at the GNPs surface (Figure 2A). However, 
both the hydrodynamic size and the zeta potential stayed unchanged even at the 
highest Raman reporter surface coverage (Figure 2B). 
 
3.1.1.1 SERS signal enhancement 
The amplification of the fingerprint spectrum as soon as the Raman reporter comes in 
contact with the GNPs surface can be observed by comparing the spectra of 1,4-BDT 
free or immobilized on gold colloidal suspension (Figure 3). Both spectra exhibited 
several peaks including two strong bands at 1’068 cm-1 and 1’556 cm-1, corresponding 
to ring breathing and ring stretching vibrations, respectively, while the Raman mode at 
2’556 cm-1 was visible only in the spectrum of free 1,4-BDT. 
 
Figure 3. SERS enhancement mechanism. Raman spectrum of 1 M free 1,4-BDT used as reference 
solution (gray curve) and SERS spectrum of 10-fold excess 1,4-BDT absorbed on gold surface (black curve). 
Arrows indicate the two most characteristic bands of 1,4-BDT at 1’058 cm-1 and 1’556 cm-1, corresponding 
to ring breathing and ring stretching vibrations, respectively. Measurements done with confocal Raman 
microscope (WITec GmbH, Germany), λex 785 nm, laser power 60 mW, integration time 0.5 s, 
accumulation 10, 100x objective.  
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3.1.1.2 Influence of Raman reporter surface coverage on SERS intensity 
SERS spectra were collected to determine how intensity changes in relation to 
increasing Raman reporter surface coverages and to identify the one giving the 
strongest signal for a clear detection of GNPs during imaging. Equal concentrations of 
GNPs were used to get rid of any variation due to different number of particles. 
Experimental measurements showed that the enhancement of SERS signal followed the 
actual amount of 1,4-BDT for surface coverages up to 100% and reached the saturation 
at 10-fold excess despite amount 1,4-BDT was approx. 4-fold higher (8-fold higher 
amount of sulfur per Au) as quantified by inductively coupled plasma mass spectrometry 
(ICP-MS) analysis (Figure 4). 
 
Figure 4. Influence of Raman reporter surface coverage on SERS intensity. Intensity of SERS signal at 
1’058 cm-1 relative to increasing 1,4-BDT surface coverages. Raman measurements done with confocal 
Raman microscope (WITec GmbH, Germany), λex 785 nm, laser power 50 mW, integration time 0.5 s, 10 
accumulations, 50x objective, ***p≤0.001, ****p≤0.0001 vs 10% 1,4-BDT surface coverage, n=3, mean ± 
SD. Amount of sulfur per Au was quantified with 8800 ICP-qqq-MS instrument (Agilent technologies), n=2, 
mean ± SD. 
 
3.1.2 PEGylation for improved stability and biocompatibility 
PEG is considered the gold-standard cloaking agent to increase stability and 
biocompatibility of nanoparticles. Furthermore, it can act as linker for antibody 
conjugation. Therefore, GNPs were functionalized with a mixture of bifunctional linkers, 
cPEG and mPEG. SERS spectrum of PEGylated GNPs ensured that PEG coating did not 
displace the Raman reporter and did not interfere with its detection (data not shown). 
Particles without 1,4-BDT reached dimensions up to 90 nm, while hydrodynamic size 
10 25 50 100 10x 100
0
200
400
600
800
000
006
025
050
1,4-BDT surface coverage (%)
SE
R
S 
at
 1
0
58
 c
m
-1 Su
lfu
r p
er A
u***
****
 45 
gradually decreased with 10 and 25% Raman reporter surface coverages and stayed 
constant at 75 nm when 50% and higher percentages of Raman reporter were applied 
(Figure 5A). Zeta potential measurements and ICP-MS analysis (Figure 5B) showed 
higher surface charge values and amounts of sulfur per Au, respectively, after 
immobilization of mPEG independently on the surface coverage of 1,4-BDT applied in 
the previous functionalization step.  
 
Figure 5. Chemico-physical properties of unconjugated GNPs. A) Hydrodynamic size and zeta potential 
measurements depending on increasing 1,4-BDT surface coverages. Analysis done with Zetasizer ZS 
dynamic light scattering instrument (Malvern Panalytical Ltd, UK), T 25°C, pH 7, n=3, mean ± SD. B) 
Amount of sulfur per Au of immobilized PEG quantified with 8800 ICP-qqq-MS instrument (Agilent 
technologies), n=2, mean ± SD. 
 
3.1.3 Anti-EGFR mediated active targeting 
To promote active targeting of tumor cells, as the last step of surface functionalization, 
increasing surface coverages of anti-EGFR antibody, from 3 to 30%, were covalently 
conjugated to the carboxy terminal groups of cPEG. To differentiate active targeting 
from passive accumulation, unconjugated GNPs (GNPs with no antibodies) were used 
as negative control. Despite antibody immobilization was not always accompanied by a 
clear increase in size or a change in surface charge (Figure 6A), successful conjugation 
was corroborated by detecting anti-EGFR antibodies with immunofluorescence analysis 
(Figure 6B). Furthermore, quantification of the number of antibodies per GNP, modified 
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with 10% Raman reporter surface coverage, relieved that the highest conjugation 
efficiency of 40% was achieved with 3% anti-EGFR antibody surface coverage.  
 
Figure 6. Anti-EGFR antibody conjugation to PEGylated GNPs. A) Hydrodynamic size and zeta potential 
depending on increasing anti-EGFR antibody surface coverages. Analysis done with Zetasizer ZS dynamic 
light scattering instrument (Malvern Panalytical Ltd, UK), T 25°C, pH 7, n=3, mean ± SD. B) 
Immunofluorescence detection of anti-EGFR antibodies on GNPs. Anti-EGFR and unconjugated GNPs 
encased by 100% 1,4-BDT were incubated with fluorescent secondary antibody and imaging was 
performed with Odyssey infrared imaging system (Li-cor, Biosciences).  
 
Conversely, it was reduced to 16.5 and 5% when 7.5 and 30% anti-EGFR antibody surface 
coverages were used, respectively (Table 2). Therefore, 3% anti-EGFR antibody surface 
coverage was chosen to produce tumor cell specific GNPs. 
 
Raman 
reporter 
surface 
coverage (%) 
Anti-EGFR 
antibody 
surface 
coverage (%) 
Theoretical 
anti-EGFR 
antibodies 
per GNP 
Empirical 
anti-EGFR 
antibodies 
per GNP 
Conjugation 
efficiency 
(%) 
10 
3 164 64±4 40 
7.5 410 67±10 16.5 
30 1’640 84±9 5 
 
Table 2. Anti-EGFR antibody immobilization on GNPs. GNPs with 10% 1,4-BDT were conjugated to 
increasing surface coverages of anti-EGFR antibody. Theoretical and effective number of antibodies per 
GNP and relative conjugation efficiency are reported. 
 
3.1.4 Anti-EGFR GNPs bio-functionality and stability in cell culture 
medium 
Functionality of anti-EGFR GNPs is an essential requirement to achieve active targeting. 
Therefore, it was evaluated first through immune dot blot. Human recombinant EGFR 
B 
Anti-EGFR GNPs 
Unconjugated GNPs 
A 
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was spotted on a nitrocellulose membrane and probed with anti-EGFR or unconjugated 
GNPs. A pink spot was visualized only upon binding of anti-EGFR GNPs, confirming 
antibody bio-activity and binding specificity (Figure 7A). Results were confirmed by 
western blot (Figure 7B).  
 
Figure 7. Bio-functionality of anti-EGFR GNPs. Human recombinant EGFR was spotted (A) on a 
nitrocellulose membrane or (B) run through a gel, transferred to a PDVF membrane and imaged with 
Odyssey infrared imaging system (Li-cor, Biosciences). Bound GNPs were evaluated through the presence 
of a bright pink spot or a fluorescence band at the expected EGFR molecular weight of 70 kDa.  
 
Long term stability of GNPs introduced to biological environment is critical since it is 
directly linked to the cellular response outcomes. To test their stability, anti-EGFR and 
unconjugated GNPs were mixed with Dulbecco’s Modified Eagle’s Medium - high 
glucose (DMEM) supplemented with 10% fetal calf serum (FCS) in a ratio of 1:2 and kept 
at 37°C. Absorbance was measured at 450 nm at multiple time points over 24 h (Figure 
8). Slightly increase was observed during the first 4 h, likely due to evaporation, but 
stayed constant over the remaining 20 h vouching the stability of GNPs in biological 
medium. 
 
Figure 8. Stability of anti-EGFR and unconjugated GNPs in cell culture medium. GNPs were incubated in 
DMEM + 10% FCS (1:2) and mixed at 37°C at 450 rpm. Absorbance was measured at 450 nm at multiple 
time points over 24 h, n=3, mean ± SD. Data obtained with Sinergy H1 microplate reader (BioTek 
Instrument, GmbH). 
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3.2 In vitro cancer cell targeting by anti-EGFR GNPs 
3.2.1 Cellular EGFR expression 
SERS tag specificity was evaluated on EGFR-positive GBM cell lines, LN229wtEGFR, 
BS153 and U87MG. Decreasing levels of EGFR expression were confirmed by 
immunofluorescent staining (Figure 9A) and western blot (Figure 9B).  
Figure 9. Different expression levels of the EGFR protein in GBM cell lines. A) Immunofluorescent 
staining of EGFR-positive GBM cells (LN229wtEGFR, BS153 and U87MG) and immortalized glial cell line 
IMA2.1 used as negative control. Nuclei stained in blue and EGFR in green. Pictures taken with DMRE 
microscope (Leica Microsystem). Scale bar 50 µm. B) Western blot: EGFR detected at 170 kDa and actin 
at 42 kDa, EGFRvIII detected at 145 kDa in BS153. C) Number of receptors per cell quantified by qFACS, 
n=3, mean ± SD.  
 
LN
22
9w
tE
GF
R
BS
15
3
U8
7M
G
IM
A2
.1
0
1×10⁵
2×10⁵
3×10⁵
4×10⁵
5×10⁵
N
°	
o
f	
EG
FR
	p
er
	c
el
l
38 kDa - 
160kDa - 
Actin 
EGFR 
EGFRvIII 
A 
B C 
 49 
In addition to EGFR, BS153 also expressed EGFRvIII as ascertained by the presence of a 
second lower band detected at 145 kDa. The number of EGFR was found to be 36 x 104 
25 x 104 and 5 x 104 per cell, respectively, as quantified by quantitative fluorescence-
activated cell sorting (qFACS) (Figure 9C). In contrast, immortalized murine astrocytes 
IMA2.1 were used as EGFR-negative cell line. 
 
3.2.2 Cellular viability response to GNPs  
Whether GNPs produce or not adverse effects is still contradictory. Therefore, cellular 
viability in the presence of GNPs was investigated by incubating LN229wtEGFR with 4 x 
105 anti-EGFR or unconjugated GNPs per cell. This amount was chosen to ensure 
complete saturation of EGFR at the cell surface. After 24 h of exposure, cells did not 
show decreased viability compared to the untreated ones confirming the lack of any 
noticeable toxicity of GNPs (Figure 10). Consistently, 4 x 105 or lower number of GNPs 
per cell were used in the following experiments (from now on expressed as µg/ml).  
 
   
 
 
 
 
 
 
Figure 10. Absence of GNPs cytotoxicity. The release of formazan was 
determined after 24 h of incubation of LN229wtEGFR cells with 4 x 105 
anti-EGFR or unconjugated GNPs/cell. Absorbance was read at 450 nm 
using FlexStation 3 microplate reader (Molecular Device, LCC). Values 
expressed as percentage of negative control (untreated cells), n=3, 
mean ± SD. 
 
3.2.3 SERS based imaging of GBM cells 
For SERS based imaging of anti-EGFR GNP-marked tumor cells, GNPs with 100% Raman 
reporter surface coverage and coupled with 3% anti-EGFR antibodies were used, unless 
otherwise specified, since they provided the strongest Raman signal for a fast and sharp 
detection of tumor cells. From now on, Raman maps were generated by plotting the 
SERS signal of Raman reporter bands at 1’058 cm-1 and 1’556 cm-1. The brighter the 
color, the higher the number of GNPs attached to the cells. Measurements were done 
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with confocal Raman microscope (Witec, GmbH, Germany) according to the following 
setting: λex 785 nm, laser power 25 mW, integration time 0.05 sec, 50x objective. Raman 
pictures are reported with the same scale in order to make Raman intensity comparable. 
 
3.2.3.1 Time-dependent binding of anti-EGFR GNPs on EGFR-positive GBM cells 
To determine how cellular accumulation of GNPs varies with time, LN229wtEGFR and 
IMA2.1 cells were incubated with 15 µg/ml of anti-EGFR or unconjugated GNPs for 30 
min, 1, 4, 8 and 24 h. The longer the incubation, the higher the amount of anti-EGFR 
GNPs taken up by LN229wtEGFR as revealed by fluorescence and Raman analysis (Figure  
 11A).                   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11. Time-dependent 
binding of anti-EGFR GNPs on 
EGFR-positive GBM cells. 
A) Time-dependent uptake of 
anti-EGFR GNPs incubated with 
LN229wtEGFR cells for 30 min, 
1, 4, 8 and 24 h and detected by 
fluorescent staining and 
Raman. 
B) Time-dependent specificity 
of the binding of anti-EGFR or 
unconjugated GNPs incubated 
with LN229wtEGFR or IMA2.1 
cells for 4, 8 and 24 h. Scale bar 
30 µm. 
 
A 
B 
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However, incubation times longer than 4 h led to non-specific uptake of anti-EGFR GNPs 
by IMA2.1 cells and unconjugated GNPs by LN229wtEGFR cells (Figure 11B). 
Consistently, incubation time was fixed at 4 h for the subsequent experiments. 
 
3.2.3.2 Time-dependent uptake and localization of anti-EGFR GNPs on EGFR-positive 
GBM cells 
Confocal fluorescence pictures of LN229wtEGFR cells incubated with anti-EGFR GNPs 
were captured to investigate their cellular uptake over 24 h. Co-localization staining was 
performed to track the intracellular fate of endocytosed GNPs. 
 
Figure 12. Time-dependent uptake and localization of anti-EGFR GNPs on EGFR-positive GBM cells. Anti-
EGFR GNPs were incubated with LN229wtEGFR cells to monitor their cellular distribution after 30 min, 1, 
4 and 24 h. Anti-EGFR antibodies on anti-EGFR GNPs were detected in green, lysosomes in red and nuclei 
in blue. Pictures were taken with laser confocal fluorescence microscope FV1000D (Olympus) and 
acquisition setting was changed at 30 min and 1 h to allow GNPs visualization. Scale bar 10 µm. 
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As shown in figure 12, weak uptake already started after 30 min of incubation and 
became stronger at 1 h. At 4 h, upon endocytosis, anti-EGFR GNPs moved to the 
lysosomes as proved by perinuclear co-localization (yellow spot) of anti-EGFR GNPs and 
lysosomes. Despite fluorescence signal was detected even in the cytoplasm, anti-EGFR 
GNPs were found to be mainly distributed at the cellular surface as expected since EGFR 
protein is located at the cellular membrane. This was more evident after 24 h of 
incubation. 
 
3.2.3.3 Influence of cellular EGFR expression level on anti-EGFR GNPs binding 
To assess the influence of different expression of EGFR at the cell membrane on anti-
EGFR GNPs binding, LN229wtEGFR, BS153, U87MG and IMA2.1 cells were incubated 
with decreasing concentrations of anti-EGFR GNPs (70, 22, 5 g/ml). Raman detection 
of anti-EGFR GNPs showed that signal increased in a concentration-dependent manner 
(Figure 13). Gathered GNPs were not sufficient at 5 g/ml. Conversely, at 70 g/ml 
amount of anti-EGFR GNPs was as much adequate as necessary for strong signal and 
distribution was uniform allowing a clear delineation of the cell shape. 
 
Figure 13. Effect of different EGFR expression level on anti-EGFR GNPs binding. LN229wtEGFR, BS153, 
U87MG and IMA2.1 cells were incubated with decreasing concentrations of anti-EGFR GNPs for 4 h and 
detected by Raman. Scale bar 30 µm. 
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However, absorption of anti-EGFR GNPs on IMA2.1 was too high. At 22 g/ml, 
discrimination between EGFR-positive GBM and EGFR-negative cell lines was possible, 
and a comparable high Raman signal intensity was detected among the different GBM 
cell lines independent on the expression level of EGFR. Therefore, the concentration of 
22 g/ml anti-EGFR GNPs was further used. 
 
3.2.4 Drawbacks of Raman reporter monolayer surface coverage  
After conjugation of anti-EGFR antibodies, reproducibility of GNPs with 100% Raman 
reporter surface coverage appeared to be problematic due to frequent and random 
aggregation. This was revealed by significant changes in the absorption spectrum (Figure 
14A), size (Figure 14B) and color of gold suspension from pink to violet (Figure 14C). In 
the worst-case aggregation followed by precipitation was noticed (Figure 14D). 
 
Figure 14. Aggregation of GNPs with 100% Raman reporter surface coverage after anti-EGFR antibodies 
conjugation. A) Red shift and broadening of the absorption spectrum. UV-Vis extinction spectra acquired 
with Sinergy H1 microplate reader (BioTek Instrument, GmbH). B) Doubling of the size. Analysis done with 
Zetasizer ZS dynamic light scattering instrument (Malvern Panalytical Ltd, UK), T 25°C, pH 7, n=3, mean ± 
SD. C) Change of the color suspension from pink to violet. D) In case of precipitation suspension color 
turned to transparent. 
A B 
C D 
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Figure 15. Impaired cell discrimination due to sedimentation and non-specific binding of GNPs. Anti-
EGFR or unconjugated GNPs were incubated with LN229wtEGFR or IMA2.1 cells and detected by 
fluorescent staining and Raman. Scale bar 30 µm. 
 
In addition, GNPs sedimentation and non-specific binding were two main concerns to 
face (Figure 15). In attempting to overcome these inconveniences, two new 
experimental setups were tested and concentration of GNPs was decreased. First, 
LN229wtEGFR or IMA2.1 cells were incubated in suspension with 5 µg/ml of anti-EGFR 
GNPs at 37°C (Figure 16A). Incubation time was only 1 h since this setup was performed 
out of the incubator to allow the shaking at 400 rpm in the thermomixer. 
Second, BS153 or IMA2.1 cells were incubated with 10 µg/ml of anti-EGFR GNPs for 4 h, 
but the plate was kept under agitation throughout the duration of the incubation 
(Figure 16B). Raman analysis showed that sedimentation was completely solved with 
both settings, but non-specific binding persisted even at lower concentrations of anti-
EGFR or unconjugated GNPs (data not shown). Because of similar outcomes and to avoid 
cellular stress due to the depletion of C02 when cells are kept outside of the incubator, 
the first setup was abandoned, while agitation was kept for the following experiments. 
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Figure 16. Persistence of non-specific binding. Anti-EGFR or unconjugated GNPs were incubated with 
GBM (LN229wtEGFR or BS153) or IMA2.1 cells (A) in suspension for 1 h or (B) under agitation for 4 h and 
detected by fluorescent staining and Raman. Scale bar 30 µm. 
A 
B 
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3.2.4.1 Modulation of surface charge of GNPs for minimizing non-specific binding 
 
Figure 17. Influence of surface charge on GNPs binding. At 2 h from antibody incubation, anti-EGFR and 
unconjugated GNPs were further modified with (A) ethanolamine or (B) aPEG. Anti-EGFR or unconjugated 
GNPs were incubated with BS153 or IMA2.1 cells under agitation and detected by fluorescent staining 
and Raman. Scale bar 30 µm. 
A 
B 
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Surface charge is known to be one of the parameters influencing GNPs binding. Indeed, 
GNPs contain a lot of carboxy terminal groups, which are negatively charged at pH 7. 
Blocking agents replace the carboxy groups with hydroxy or methoxy groups making 
GNPs less negatively charged. In order to reduce non-specific binding, surface charge 
was manipulated by adding an excess of blocking agents such as ethanolamine or 
amino-PEG-methoxy (aPEG) after either 2 h or overnight incubation of GNPs with anti-
EGFR antibodies. The adjunct of 1% ethanolamine after 2 h caused the depletion of 
Raman and fluorescent signal even on BS153 incubated with 10 µg/ml of anti-EGFR 
GNPs (Figure 17A). Conversely, the addition of 1% ethanolamine after overnight 
incubation or excess of aPEG after 30 min, 2 h or overnight incubation did not interfere 
with antibody conjugation as confirmed by the restored, even though weak, fluorescent 
signal on BS153 cells (Figure 17B). However, it did not improve the non-specific binding 
of anti-EGFR GNPs on IMA2.1 or the passive absorption of unconjugated GNPs on BS153 
cells. 
 
3.2.4.2 Effect of PEG coating on non-specific binding and SERS sensitivity 
To prove that the ratio of 1,4-BDT and PEG affects the binding specificity, SERS signal 
was measured after incubation of BS153, U87MG and IMA2.1 cells with 10 µg/ml of anti-
EGFR GNPs carrying increasing amounts of Raman reporter. As negative control, BS153 
cells were incubated with same amount of unconjugated GNPs (Figure 18A). 
Under these conditions, the strongest SERS signal was acquired on cells exposed to 
GNPs with 100% Raman reporter surface coverage as confirmed by its quantification, 
but it co-occurred with non-specific binding of GNPs on the two negative controls 
resulting in false positive results. Increased PEG surface coverage, as a consequence of 
lower surface coverage of 1,4-BDT, minimized progressively the non-specific binding in 
IMA2.1 incubated with anti-EGFR GNPs (80% decrease and no signal with 50% and lower 
surface coverages of 1,4-BDT, respectively) and in BS153 incubated with unconjugated 
GNPs (unchanged, 93% decrease and no signal with 50, 25 and 10% surface coverages 
of 1,4-BDT, respectively). Moreover, the lower the Raman reporter surface coverage, 
the smaller the SERS signal intensity in BS153 (unchanged, 98 and 99% decrease with 
50, 25 and 10% surface coverages of 1,4-BDT, respectively) and in U87MG (40, 96 and 
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98% decrease with 50, 25 and 10% surface coverages of 1,4-BDT, respectively) 
incubated with anti-EGFR GNPs. To note that, in BS153 and in U87MG exposed to anti-
EGFR GNPs encased by 10 and 25% surface coverages of 1,4-BDT, the detected signal 
was attributable to isolated particles and its intensity was not considered strong enough 
for a clear discrimination between EGFR-positive GBM and EGFR-negative cells. 
 
Figure 18. Increased PEG surface coverage minimized non-specific binding. EGFR-positive GBM (BS153 
and U87MG) and EGFR-negative (IMA2.1) cells were incubated with anti-EGFR or unconjugated GNPs 
functionalized with increasing surface coverages of 1,4-BDT and detected by Raman. Quantification of 
relative SERS signal is reported below. Pictures of three random areas for each specimen were 
transformed in 16-bit images and signal was quantified with Image J software. *p≤0.05, **p≤0.01, 
****p≤0.0001 vs 100% 1,4-BDT, n=3, mean ± SD. Scale bar 30 µm. 
 
GNPs with 10% surface coverage of 1,4-BDT coupled to 84 anti-EGFR antibodies (as 
quantified in section 3.1.3) were used to improve binding ability and to boost the SERS 
signal accordingly. However, Raman detection did not raise (Figure 19) not even after 
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increasing the concentration of GNPs or the laser power (data not shown). Decreased 
Raman signal was not ascribed to the absence of the GNPs on the cells whose presence 
was confirmed by immunofluorescent staining and dark field analysis. Indeed, due to 
the strong SPR light scattering, GNPs were visualized as bright points further confirming 
the binding specificity due to higher PEG surface coverage. It was not even ascribed to 
the displacement of the Raman marker from the GNPs surface as proven by the 
detection of its fingerprint spectrum in the supernatant collected after incubation with 
cells (data not shown). 
 
Figure 19. Reduced SERS signal of GNPs with 10% Raman reporter surface coverage. BS153 and IMA2.1 
cells were incubated with GNPs coupled to 84 anti-EGFR antibodies. Unconjugated GNPs were incubated 
with BS153 cells. Anti-EGFR GNPs were detected by fluorescent staining, Raman (scale bare 30 µM) and 
as bright points by dark field microscopy (pictures taken with hyperspectral imaging system, CytoViva, 
Inc, US, scale bar 50 µM). 
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Based on these results, GNPs functionalized with 50% Raman reporter and 50% PEG 
showed the balanced chemistry surface to enable a clear detection of GNPs while 
reducing non-specific binding. Further, improved binding specificity was confirmed by 
transmission electron microscopy imaging that showed a higher number of anti-EGFR 
GNPs internalized by BS153 cells compared to the negative controls (Figure 20). 
Consistently, these particles were used for further in vitro experiments. 
 
Figure 20. Improved binding specificity of GNPs with balanced surface chemistry. Transmission electron 
microscopy pictures of BS153 and IMA2.1 cells incubated with anti-EGFR or unconjugated GNPs 
functionalized with 50% Raman reporter and 50% PEG. Red circles highlight internalized particles. Images 
captured with FEI Tecnai T12 transmission electron microscope, acceleration voltage 80 kV. Scale bar 1 
µM. 
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3.3 In vitro studies of GNPs transit through the BBB 
A major concern of targeting brain tumor cells is the ability of GNPs to cross the BBB. 
This was evaluated in vitro using a transwell BBB model. The simplest form of transwell 
model consists of a monoculture of brain endothelial cells seeded on the apical surface 
of a support filter as shown in figure 20. 
 
 
 
 
Figure 21. Illustrative 
representation of an in vitro 
transwell BBB model [104]. 
 
3.3.1 Characterization of the BBB model 
The human brain endothelial cells, hCMEC/D3 (referred as D3), were used for the 
creation of the BBB model. Formation of a continuous and functional tight monolayer 
was observed after 5 days of culture on the insert membrane. Cells then expressed the 
TJs proteins ZO-1 and claudin-5 at cell-cell contacts (Figure 21A).  
 
Figure 22. BBB model characterization. A) Expression of BBB markers: TJs proteins ZO-1 and claudin-5 
were detected by fluorescent staining in green and in red, respectively. Pictures taken with Axiovert 40 
CFL microscope (Zeiss). Scale bar 50 µM. B) Paracellular permeability: 10 g/ml of LY were added to the 
apical part of the transwell and, after 1 h of incubation, aliquot was taken from the basolateral chamber 
and fluorescence read at λex 428 nm; λem 540 nm using FlexStation 3 microplate reader (Molecular Device, 
LCC). ****p≤0.0001 vs control (transwell with only collagen), n=3, mean ± SD. C) 2 x 104 cells were seeded 
into the apical part of the transwell and let attach overnight. TEER values were recorded over 10 days 
with CellZscope instrument (NanoAnalytics, GmbH); control (transwell with only collagen), n=2, mean 
± SD; D3, n=4, mean ± SD. 
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Barrier integrity was also tested by measuring its paracellular permeability to lucifer 
yellow (LY) in apical to basolateral direction. Higher restriction was exerted by the cells 
compared to the control inserts without endothelial cells (Figure 21B). Despite barrier 
formation appeared to be successful, TEER was found to remain at constant low levels 
and was only slightly higher compared to transwell inserts without cells after 5 days 
(figure 21C). Longer cell culture time up to 10 days did not help to achieve higher TEER 
values and the formation of multiple cell layers was often observed after prolonged 
period of culture.  
 
3.3.2 Transport of GNPs across the BBB 
To investigate the permeation of GNPs through the BBB, 10 and 35 µg/ml of anti-EGFR 
GNPs were added to the apical side of the inserts after 6 days of culture. After 24 h of 
incubation, the presence of gold in the basolateral medium was measured by ICP-MS.  
 
Figure 23. Passage of GNPs through an in vitro BBB. After 24 h of incubation with 10 and 35 µg/ml anti-
EGFR GNPs: A) Amount of gold was measured in the basolateral chamber with 8800 ICP-qqq-MS 
instrument (Agilent technologies), n=3, mean ± SD; B) Cell monolayer integrity was evaluated by 
measuring the paracellular permeability of LY. ****p≤0.0001 vs control (transwell with only collagen), 
n=3, mean ± SD; C) Cell viability was determined by the release of formazan. Absorbance was read at 450 
nm using FlexStation 3 microplate reader (Molecular Device, LCC). Values expressed as percentage of 
negative control (untreated cells), n=3, mean ± SD. 
 
About 0.08% and 0.1% of the applied concentrations of gold (10 e 35 µg/ml, 
respectively) were found to go through the cell monolayer and the membrane of the 
insert (Figure 22A). The effects of GNPs on BBB integrity were monitored by measuring 
A B C 
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the LY permeability (Figure 22B). Even in this case, higher restriction was exerted by the 
cells compared to the control inserts. Moreover, the permeability of the inserts exposed 
to GNPs was only slightly higher compared to the untreated cells, meaning that cell 
monolayer integrity was preserved. Furthermore, both concentrations of GNPs did not 
affect cell viability (Figure 22C). TEER values also remained unchanged after 24 h of 
incubation with 10 µg/ml of anti-EGFR GNPs as monitored in a separate experiment 
(data not shown). 
 
 
 
 
 
 
 
 
 
 
  
10x 
 64 
 
 
 
 
 
 
 
 
 
 
 
 
  
 65 
4. Discussion 
 
 
 
Improved visualization of brain tumor cells during Raman intraoperative surgery 
can be achieved by using anti-EGFR GNPs as SERS tags. Surface functionalization is 
shown to significantly influence anti-EGFR GNPs performance. Indeed, an appropriate 
combination of the functionalities immobilized on the gold surface is required, 
especially when the gold core is used as the only accessible surface for all the 
functionalities as done in this thesis. This decision was made to keep the size of anti-
EGFR GNPs as small as possible due to the requirement to cross the BBB in the clinical 
situation. Hence, the challenge was to combine the three essential components: i) 
Raman reporter for a maximal SERS signal; ii) inert, protective PEG coating to prevent 
non-specific binding; iii) and antibody with high receptor binding affinity towards tumor 
cells, in order to obtain the highest and most specific SERS signal. Finding the optimal 
balance among these three components depends on the accurate characterization of 
GNPs. This was one of the main challenges met in this project due to the limited 
sensitivity of the analytical methods available. Indeed, several techniques, such as X-ray 
photoelectron spectroscopy, Fourier-transform infrared spectroscopy or energy 
dispersive X-ray were used but none of them allowed a sensitive detection of surface 
binding ligands. Possible solution would be to scale up the production process to 
facilitate their analysis. 
 
4.1 Raman reporter to enhance SERS signal 
The SERS enhancement mechanism was confirmed by the assessment of the two 
strong Raman bands, assigned to ring breathing and ring stretching vibrations [105], 
which showed 35 and 55 times higher signals for 1,4-BDT immobilized on GNPs 
compared to free 1,4-BDT, respectively. Furthermore, characteristic SERS peaks of the 
immobilized 1,4-BDT were shifted and broadened while others disappeared. These 
changes arise because of the formation of surface complexes upon immobilization [36]. 
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Within the range of tested surface coverages, from 10 to 10-fold excess, the highest 
SERS signal was recorded at 100% 1,4-BDT.  
Despite the presence of multilayers at 10-fold excess surface coverage, SERS signal 
improved of only 18% compared to the one achieved at full monolayer surface coverage. 
This is counterintuitive since SERS enhancement is a long-range effect and extends to 
approx. 10 nm away from the metallic surface. Based on the distance dependence 
decay, a contribution of the subsequent layers from 77% to 46% for a distance of 0.8 
nm (second layer) to 2.4 nm (fourth layer), respectively, from the gold surface would be 
expected [50]. However, it is worth mentioning that metallic surface only influences 
chemically molecules in first layer. In addition, at large surface coverage, the adsorption 
geometry may vary and the LSPR and the electromagnetic properties of the Raman 
reporter may be affected [36]. The absence of the band at 536 cm-1 that usually dictates 
the formation of S-S bond [106], the relatively low coating thickness of 0.8 nm of the 
Raman reporter monolayer [51] and the protonation of thiol group at pH 6.5 - 7 further 
implied that the formation of multilayers rather involved π-π stacking than S-S bond. 
This explained the unaffected size and charge of GNPs. 
 
4.2 Inert coating to prevent non-specific adsorption  
In order to prevent non-specific interactions and for increased biocompatibility, the 
inert, protective coating of PEG was necessary. Under the assumption that the more 
complete the PEG functionalization, the better the stability and the reduction of non-
specific binding, 100% PEG surface coverage was only possible on GNPs without 1,4-
BDT. Then, the higher the surface coverage percentage of 1,4-BDT, the lower the 
amount of PEG up to inhibition of its binding for 100% Raman reporter surface coverage. 
Experimental results confirmed a progressively decreasing PEGylation process that 
however involved even GNPs with full Raman reporter surface coverage. Chen et al. 
showed that PEG conformation is dependent on its density [67]. At higher surface 
coverages it stretches out in a brush conformation explaining the increased 
hydrodynamic size up to 14 nm of GNPs functionalized with 0 to 25% 1,4-BDT (Figure 
5A, see results, page 45). Conversely, at lower surface coverages it assumes a mushroom 
configuration with a radius of gyration as low as 2.8 nm justifying the negligible change 
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in size of GNPs with 50 and 100% 1,4-BDT. However, GNPs with full Raman reporter 
surface coverage were found to be noticeably prone to random aggregation after 
conjugation of anti-EGFR antibody at surface coverages equal and higher than 3%. 
Aggregation was accompanied by an increased average size of 140 nm (consistent with 
the formation of dimers), a red shift as well as broadening of the SPR adsorption peak 
and an optical density (OD) decrease of approx. 30% (Figure 14A, see results, page 53). 
This indicated that the amount of PEG was too low to maintain GNPs stability. In the 
worst-case, GNPs with full Raman reporter surface coverage underwent aggregation 
followed by precipitation that was visibly detected by the change in color of the 
suspension from red to violet or to transparent and OD decrease to the baseline. In 
addition, GNPs with full Raman reporter surface coverage showed a stronger negative 
charge (-33 ± 0.8 mV) (Figure 6A, see results, page 46). If on one hand, value < -30 mV 
are known to make GNPs more stable due to electrostatic repulsions [107], on the other 
hand the same particles displayed a high level of non-specific binding with cells similarly 
to what observed in literature with quantum dots (QDs) [108], [109]. Moreover, the 
higher the surface coverage percentage of 1,4-BDT, the higher the degree of non-
specific binding. Indeed, GNPs with 10 and 25% Raman reporter surface coverages 
exhibited a reduction of non-specific interaction with the cell surface up to 100%. This 
had less to do with the surface charge, which was still negative (-26 ± 2.5 and -31 ± 2.2 
mV, respectively) than to the passivation of GNPs surface because of the presence of 
PEG [108]. Nonetheless, decreasing the amount of Raman reporter to 10 and 25% 
surface coverages on behalf of PEG resulted in the complete depletion of Raman 
sensitivity after incubation of GNPs with cells. This could be overcome by increasing the 
integration time (from 0.05 to 0.5 sec) or reducing the working distance (from 16.5 to 
0.3 mm). However, both methods meant longer acquisition times and are not desirable 
in view of the final clinical application.  
Consistently to what discussed so far, 50% Raman reporter surface coverage was 
identified as the percentage to achieve the optimal balance. In fact, despite a theoretical 
value of approx. 30’000 molecules of PEG per GNP has also been reported by Qian et al. 
to be necessary to stabilize gold colloids against aggregation [53], approx. 16’000 PEG 
molecules were already sufficient to prevent aggregation. 80% reduction of non-specific 
binding was observed on IMA2.1 incubated with anti-EGFR GNPs compared to the 
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particles with full Raman reporter surface coverage. Persisting non-specific binding in 
BS153 incubated with unconjugated GNPs was attributed to highly negative 
carboxylated GNPs (-34 ± 2.2 mV). A possible alternative to reduce non-specific binding, 
without affecting Raman sensitivity, was acting on GNPs surface charge by the 
deactivation of the residual carboxy-end terminated PEG with ethanolamine or aPEG. 
This strategy has been successful adopted for QDs [109] where weakening the 
electrostatic interactions led consequently to the reduction of non-specific binding with 
cell membranes. Indeed, it worked successfully for unconjugated GNPs treated with 
ethanolamine (Figure 17A, see results, page 56), whose non-specific binding was 
completely suppressed. Though, a complete suppression of antibody activity after 
deactivation of anti-EGFR GNPs was observed probably due to side reaction with the 
anti-EGFR binding sites.  
This confirmed that it is not necessary to functionalize every site on the surface of 
nanoparticles to reduce non-specific binding as also defined by Benzten et al. [108] as 
long as it is accompanied by the deactivation of negatively charged groups on GNPs 
surface (either through antibody conjugation or blocking agents). Therefore, we suggest 
using nanoparticles conjugated to a non-specific IgG as proper negative control for non-
specific binding. 
At the same time, Raman sensitivity was reduced of 40% compared to the particles with 
full Raman reporter surface coverage. However, it was high enough for a sharp 
detection of GNPs detected in the picomolar range in agreement to what reported by 
Kircher et al.[10]. 
 
4.3 Antibody concentration for improved active targeting 
PEG surface coverage influenced the GNPs stability also in terms of the possible number 
of antibodies conjugated. If, on one hand, GNPs with maximum surface coverage of 
Raman reporter were susceptible to aggregation when antibody surface coverage was 
equal or higher than 3%, on the other hand, GNPs with 10 or 25% Raman reporter 
surface coverage allowed conjugation of antibody surface coverages up to 30%. 
Independently on the amount of antibody used, the hydrodynamic size of anti-EGFR 
GNPs compared to the unconjugated ones was compatible with its horizontal 
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orientation on the GNPs surface since the length of the IgG is approximately 7−10 nm 
[110]. Despite conjugation protocol with ethyl dimethylaminopropyl carbodiimide (EDC) 
/N-hydroxysulfosuccinimide (sulfo-NHS) did not allow to control the orientation of the 
antibodies, they kept their functionality after conjugation. Even though increasing the 
number of antibodies up to 10 times in the conjugation reaction gave rise to a higher 
antibody content at the surface of GNPs, the conjugation efficiency remained 
significantly low from 40 to 5% resulting in 64 and 84 antibodies per GNP, respectively. 
Moreover, higher number of antibodies per GNP did not help enhancing the Raman 
sensitivity if compared to the lower amount and suggested that the excess of antibodies 
is not necessary for improved active binding of the GNPs to the cellular target. The 
phenomenon in which increasing the number of antibodies per GNP does not increase 
the binding affinity was already observed by Elias et al., who showed that an 
intermediate ligand density provided statistically significant improvements in cell 
binding in comparison to higher and lower densities [111]. This trend can be explained 
by examining the state in which the EGFR resides on the cellular membrane. Needham 
et al. have reported that EGFR exists as “receptor clusters” whose diameter goes from 
8 (dimers) to 57 nm (homo-polymers of 10 receptors). Considering the calculated 
number of antibodies and assuming a homogeneous distribution beside a straight and 
site control orientation of the antibodies on GNPs, there would be a maximum distance 
of 10 nm between two molecules. This would mean that only in case of dimers two 
antibodies would be able to bind two close dimers while, in case of cluster, up to 5 
antibodies would be occupied to bind several receptors in the same cluster preventing 
other GNPs from binding to the same cluster. In real conditions, inhomogeneous 
distribution and random orientation of the antibodies would rather increase the steric 
hindrance causing competition between two close molecules for a single receptor and 
limiting the access that antibodies have to the receptors [110]. Despite here retention 
of functionality was shown, investigation of the number of antibodies with unaltered 
functionality was not carried out and lack of control for ligand orientation could result 
in antibodies with reduced or eliminated functionality thus altering the perceived 
“functional” density of ligands. The size of GNPs has further to be considered since it is 
almost 90 or 30% bigger compared to one dimer or one cluster, respectively. In this case, 
the shielding would be due to cellular EGFR interaction with the nearby GNPs. The 
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considerations set out so far are summarized in figure 1. 
Anti-EGFR GNPs showed stability in cell culture medium and negligible cytotoxicity on 
GBM cells over a period of 24 h confirming what reported in literature [10]. GNPs 
selective uptake by GBM tumor cells in culture was concentration and time-dependent 
with the optimum incubation time fixed to 4 h. This is in agreement with their final 
clinical application considering that GBM surgery lasts in average 4 h. Furthermore, anti-
EGFR GNPs allowed SERS based imaging of all EGFR-positive GBM cells, including cells 
expressing EGFRvIII such as BS153, which were known not to show any fluorescence 
after 5-ALA administration [15]. This opens a new chance to visualize even those GBM 
or low-grade glioma that are known not to respond to 5-ALA treatment. 
 
Figure 1. Illustration of the principal findings. A) Correlation between increasing 1,4-BDT surface 
coverages and Raman sensitivity, cellular binding specificity, applied concentration of anti-EGFR 
antibodies, acquisition speed and gold colloidal stability. Results are presented as relative percentage to 
the highest value recorded (100%) for each parameter. B) Possible organization of EGFR on the GBM cell 
membrane and interaction with anti-EGFR GNPs. 
 
A 
B 
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4.4 Crossing the BBB 
Higher performance of anti-EGFR GNPs with 50% surface coverage of Raman reporter 
and PEG presented in this study, especially in terms of detection sensitivity and binding 
specificity, give reasons for further investigations in vivo using animal models before 
moving to the final clinical application. However, a major criticism regarding the 
injection of GNPs in vivo is their strongly limited delivery to the brain due to the BBB. 
Thus, anti-EGFR GNPs showed to be able to cross the in vitro BBB model without altering 
the barrier integrity. Indeed, about 0.1% of the initial applied concentration of GNPs was 
found in the basolateral compartment of a transwell system mimicking the BBB after 24 
h of incubation. This percentage needs to be improved but it was deemed promising 
considering the 0.3% of 10 nm GNPs or 0% of 50 or 100 nm particles present in the brain 
after intravenous administration in rats [65]. Furthermore, when working with an in 
vitro BBB model like the one described, it is worth keeping in mind technical limitations 
such as GNPs adhesion to the transwell pores of the filter or agglomeration within the 
pores, thus obstructing the transport [101]. The estimation of the delivery through the 
membrane could therefore be underestimated. Application of GNPs in animal models 
would further address some critical issues that could limit their use such as long-term 
stability in the blood circulation by escaping the opsonization processes, toxicity at 
higher dosage, possible immune responses, biodistribution and elimination from the 
body. Further, human EGFR-positive GBM cells xenograft in mice brains mimicking 
closely the BBB could pave the way for a deeper and more reliable understanding of the 
ability of anti-EGFR GNPs to reach their final targets. Despite in vivo exploration is 
mandatory, the ability of SERS based imaging to visualize in vitro GBM cells with high 
sensitivity and specificity, when GNPs are properly engineered, is promising for its 
definitive implementation in the operation room to identify and remove residual cancer 
cells for better outcomes of patients suffering from brain tumors.  
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5. Conclusions and outlooks 
 
 
 
To achieve a complete resection of GBM during surgical operation, improved 
visualization of residual cancer cells is indispensable. Raman based imaging, coupled 
with GNPs as SERS tags, offers several advantages over current visualization 
technologies as long as GNPs with high stability, Raman sensitivity and binding 
specificity to tumor cells are produced. In view of this, this work provided a noteworthy 
understanding of the influence that surface functionalization exerts on GNPs 
performance for SERS based imaging. Non-toxic SERS tags were developed with several 
ratios of inert and receptor specific active molecules. Full Raman reporter or PEG surface 
coverage maximized Raman sensitivity and binding specificity, respectively. However, 
these statements were valid only when considered individually. Therefore, the optimal 
balance among all the functionalities was identified to allow a fast, sensitive and specific 
Raman detection of GBM cells. It was even shown that higher amounts of antibody on 
the GNPs surface did not improve the cellular binding stressing that the optimal ligand 
concentration does not always match the highest. In addition, the ability of anti-EGFR 
GNPs to cross a BBB model in vitro was attested.  
With regards to GBM, whose challenging treatment pushed the start of this study, the 
results revealed the potential of SERS based imaging to visualize GBM or low-grade 
gliomas, which show variable fluorescence or do not respond after 5-ALA 
administration. Moreover, they would justify further in vivo experiments using animal 
models. A possible strategy would also involve the conjugation of more than one moiety 
on GNPs either to target two different cell types within the same tumor or to improve 
specificity toward a single cancer cell type prone to extreme heterogeneity of 
overexpressed cell surface receptors, as observed in GBM. Even using GNPs with rod 
shape could be beneficial since it would reduce significantly the size (approx. 3 times 
smaller) of conjugated particles facilitating their ability to cross the BBB and to reach 
their targets. 
 74 
The considerations raised in this work can be extended to the visualization of any other 
kind of tumor and to any other application implying the use of GNPs. By clarifying the 
effect of surface chemistry on SERS tags specificity, affinity and sensitivity, this work 
adds new aspect to the current literature. It also highlights the need to perform a 
detailed characterization of SERS tags to clearly distinguish between theoretical added 
functionalities and the ones effectively present on the surface of the nanoparticles. Only 
the conscious knowledge of SERS tags properties allows to achieve a system with high 
reproducibility and reliability to give to the clinicians an adequate tool to reduce the 
occurrence of relapses thus improving patients survival. 
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6. Materials and methods 
 
 
 
6.1 Nanoparticles functionalization 
Ultrapure water (18.2 mΩ/cm) was used throughout the work. GNPs suspension, 
dimethyl sulfoxide (DMSO) and 0.1 mM phosphate buffered saline (PBS) were degassed 
under nitrogen in the ultrasound for 1 h. Citrate stabilized GNPs (60 nm diameter) were 
used. Raman reporter, 1,4-BDT, was dissolved in DMSO and 0, 1, 2, 4 or 40 µl of 1 mM 
solution were added to 1 ml of GNPs suspension (1.9 x 1010 particles per ml) and 
sonicated for 1 h at 25°C. 400 µl of 0.4 µM cPEG (3.5 kDa) solution were added to the 
Raman active GNPs before sonication for 1 h at 25°C followed by mixing for 4 h at 25°C 
at 750 rpm. 600 µl of 10 µM mPEG (5 kDa) were added and samples were incubated 
overnight at 25°C at 750 rpm. To remove the excess of PEG, samples were centrifuged 
for 30 min at 4’500 rpm and resuspended in 1 ml of 0.1 mM PBS. To activate the carboxy 
groups, 200 µl of 5 µM EDC/sulfo-NHS mixture were added to the samples and mixed 
for 20 min at 25°C at 750 rpm. To remove the excess of EDC/sulfo-NHS, samples were 
centrifuged for 30 min at 4’500 rpm and resuspended in 0.5 ml of 20 mM 4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) buffer, pH 7.4. Activated 
carboxy groups were covalently linked to 4, 10 or 40 µl of 200 µg/ml rabbit anti-EGFR 
antibody (10001-R021) for 2 h at 25° C at 750 rpm and the mixture was kept overnight 
at 4°C. Unbound antibodies were separated from anti-EGFR GNPs by two 
centrifugations for 30 min at 4’500 rpm. The final pellet was resuspended in 0.1 mM PBS 
and stored at 4°C. Unconjugated GNPs were synthetized by using the same procedure 
but 0.1 mM PBS was added instead of anti-EGFR antibodies. To modulate surface charge 
of GNPs, 1% (v/v) ethanolamine or 1 µl of 1.5 mM solution of aPEG (750 Da) was added 
to anti-EGFR and unconjugated GNPs either after 2 h or overnight incubation of GNPs 
with anti-EGFR antibodies. All chemicals were purchased from Sigma-Aldrich, except 
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mPEG and anti-human EGFR antibody that were obtained from Rapp polymere and Sino 
biological, respectively. 
 
6.1.1 Nanoparticles characterization 
UV-Vis spectra were acquired in the range 400-700 nm, 1 nm step, with Sinergy H1 
microplate reader (BioTek Instrument, GmbH). GNPs concentration was calculated by 
using a calibration curve (R2=0.9988) from known concentrations of bare GNPs and 
relative absorbance at 450 nm.  
 
Hydrodynamic size distribution by Dynamic light scattering and zeta potential were 
determined with Zetasizer ZS dynamic light scattering instrument (Malvern Panalytical 
Ltd, UK). Each sample was measured at 25°C, pH 7.  
 
For transmission electron microscopy analysis, 2 µl of bare GNPs were placed onto 
standard 3.5 mm transmission electron microscopy grid (Formvar/Carbon 200 Mesh, 
Copper grids). After drying, grid was rinsed with milliQ water and visualized with EM 900 
transmission electron microscope (Zeiss), acceleration voltage 50 kV.  
 
SERS spectra of dry GNPs were recorded with confocal Raman alpha300 R microscope 
(Witec, GmbH, Germany) equipped with a 785 nm excitation wavelength. Laser power 
was set at 50 mW with an integration time of 0.5 sec, 10 accumulations, 50x objective 
unless otherwise specified. Spectra were processed with Witec Project 4.1 software. 
 
ICP-MS was used to quantify the amount of gold and thiol ligand (by sulfur 
measurement). To avoid overestimation of sulfur, GNPs were functionalized as 
described above but acetone, instead of DMSO, was used to dissolve 1,4-BDT. 
Quantification was carried out using an external calibration from single-element 
standards (Sigma-Aldrich) prepared in milliQ water from 0-100 µg/L. Samples were 
diluted accordingly and analyzed with 8800 ICP-qqq-MS system (Agilent technologies). 
Au quantification was performed on 197Au+ using helium as a collision gas (5 ml/min), 
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32S+ was measured in triple quad mass-shift mode using O2 as a reaction gas. 103Rh+ was 
used as an internal standard to account for possible matrix effects.  
 
6.1.2 Quantification of the number of antibodies per nanoparticle 
To quantify the number of antibodies per GNP, an excess of Alexa Fluor® 680 goat anti-
rabbit antibody (Invitrogen) was added to the anti-EGFR and unconjugated GNPs. 
Known concentrations of the antibody were used to prepare a standard curve. Samples 
and the standards were mixed for 1 h at 25°C at 450 rpm. Samples were then washed 
twice with PBS 0.1 mM for 15 min at 4’500 rpm to remove any residual free antibody. 
Fluorescence detection was performed with Odyssey® CLx infrared imaging system (Li-
cor, Biosciences). The fluorescence of unconjugated GNPs was used to estimate the 
fluorescence signal due to absorbance by GNPs and the non-specific binding of 
secondary antibody. The number of antibodies per GNP was determined by using the 
calibration curve (R2=0.98581) and by normalizing the result to total amount of GNPs in 
the sample as measured by absorbance values.  
 
6.1.3 Nanoparticles optical stability in cell culture medium 
To evaluate the impact of biological media on GNPs stability, anti-EGFR and 
unconjugated GNPs were diluted 1:2 in DMEM (Sigma-Aldrich) supplemented with 10% 
FCS (Sigma-Aldrich) and 1% penicillin–streptomycin (P/S) (Sigma-Aldrich). Samples were 
run for 24 h at 37°C at 450 rpm. Absorbance at 450 nm was measured after 0, 1, 2, 4, 6, 
8 and 24 h.  
 
6.1.4 Immuno dot blot  
Antibody functionality after conjugation onto GNPs was evaluated by immuno dot blot. 
2 µl of 250 µg/ml human recombinant EGFR (Sino Biological) were spotted onto 
nitrocellulose membrane (GE Healthcare). After blocking with 1% (w/v) dry milk for 30 
min at room temperature (RT), membrane was incubated with 70 µl of 40 µg/ml anti-
EGFR or unconjugated GNPs for 3 h at RT. Membrane was washed three times for 5 min 
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with blocking solution and the presence of bound GNPs (bright pink spot) was visually 
evaluated. 
 
6.2 Cell culture 
The following cell lines were used to carry out in vitro experiments: the human GBM cell 
line U87MG was obtained from ATCC; the human GBM cell line BS153 was provided by 
Prof. Monika Hegi (University Hospital Lausanne, Switzerland); the human GBM cell line 
LN229, overexpressing the EGFR gene (LN229wtEGFR), was provided by Prof. Michael 
Weller (University Hospital Zürich, Switzerland); the immortalized astrocyte cell line 
IMA2.1 was provided by Dr. Stefan Schildknecht (University of Konstanz, Germany) and 
was used as EGFR-negative cell line. Cells were cultured in DMEM, supplemented with 
10% FCS and 1% P/S. To maintain high EGFR expression level in LN229wtEGFR, medium 
was enriched with 60 µg/ml hygromycin B (Sigma-Aldrich). All the cells were kept at 
37°C, in a 5% CO2 atmosphere. 
 
6.2.1 Fluorescence staining 
Cellular EGFR expression was investigated by fluorescent immunocytochemistry. At 80% 
confluency, cells were fixed with 4% (v/v) paraformaldehyde (PFA) (Thermofisher 
Scientific) for 10 min at RT and permeabilized with 0.2% (v/v) Triton X-100 in PBS + 5% 
(v/v) normal donkey serum (NDS) for 20 min at RT. Cells were incubated with rabbit anti-
human EGFR antibody, diluted 1:250, overnight at 4°C, then with FITC donkey anti-
rabbit antibody (Jackson ImmunoResearch), diluted 1:300, for 1 h at RT. Cell nuclei were 
stained with 300 nM DAPI (Sigma-Aldrich) added to the secondary antibody. Slides were 
mounted in FluorSave™ Reagent (Calbiochem) and pictures taken with a F-View camera 
coupled to DMRE microscope (Leica Microsystem). Washings with PBS were performed 
between each step for 5 min each. 
 
6.2.2 Western blot 
Cellular EGFR expression was evaluated by western blot. Whole-cell extracts were 
obtained by lysing cell pellets in radioimmunoprecipitation assay buffer enriched with 
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protease inhibitors (Sigma-Aldrich), diluted 1:100. Protein concentration was 
determined using the bicinchoninic acid protein assay kit (Thermofisher Scientific). 30 
µg of protein extracts were separated in a 8% precast polyacrylamide gel (Invitrogen) 
and transferred onto polyvinylidene difluoride (PVDF) membrane (Merk Millipore) by 
wet electroblotting. Membrane was blocked with Odyssey® blocking buffer (Li-cor, 
Biosciences) for 1 h at RT and incubated with rabbit anti-human EGFR and goat anti-
human actin antibodies (Abcam), diluted 1:500 and 1:1’000 respectively, overnight at 
4°C. IRDye® 680 donkey anti-goat (Li-cor, Biosciences) and Alexa Fluor® 680 goat anti-
rabbit antibodies, diluted 1:10’000, were then added for 1h at RT. Blot was scanned with 
Odyssey® CLx infrared imaging system (Li-cor, Biosciences). Washings with PBS-T were 
performed between each step for 5 min each. 
 
For the evaluation of antibody functionality after conjugation onto GNPs, human 
recombinant EGFR protein (1.9 µg) was separated in a 8% precast polyacrylamide. 
Protein was transferred onto PVDF membrane by wet electroblotting and incubated 
with anti-EGFR or unconjugated GNPs for 3 h at RT. Anti-EGFR antibodies on GNPs were 
probed with Alexa Fluor® 680 goat anti-rabbit antibody, diluted 1:10’000. Blot was then 
scanned with Odyssey® CLx infrared imaging system (Li-cor, Biosciences). 
 
6.2.3 Quantitative expression of EGFR at the cell membrane  
To quantify EGFR expressed at the cell membrane of each cell line, qFACS was 
performed by using QIFIKIT®* (Dako) according to the manufacturer’s instructions. 
Briefly, 106 cells/ml were incubated with a saturating concentration (1 µg/ml) of mouse 
anti-human EGFR antibody (BioXCell) for 1 h at 4°C in the dark. Incubation without 
primary antibody served as negative control. To prevent EGFR internalization, cells were 
washed for 5 min at 4°C at 2’500 rpm and fixed with 1% PFA for 10 min at RT and 
incubated with FITC goat anti-mouse antibody (supplied in the kit) diluted 1:50 for 45 
min at 4°C in the dark. Cells were centrifuged three times for 5 min at 4°C at 2’500 rpm 
and resuspended in 0.1 M Ethylenediaminetetraacetic acid + 1% (w/v) bovine serum 
albumin (BSA). Cells were analyzed with CytoFlex S flow cytometer (Beckman Coulter). 
Data were subsequently processed with FlowJo 10.4 software. EGFR density/cell was 
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obtained by comparing the mean fluorescence intensity (MFI) of the cells to the MFI of 
five populations of calibration beads with known numbers of antibody binding sites used 
to generate a standard curve. Values were corrected for the autofluorescence signal of 
cells and for unspecific binding of the secondary antibody on negative controls.  
 
6.2.4 GNPs cytotoxicity 
To determine GNPs cytotoxicity, LN229wtEGFR were plated at a density of 1 x 103 
cell/well in a 384 well plate and allowed to attach for 2 h at 37C. Then, 4 x 105 anti-
EGFR GNPs/cell were added to each well. Cells incubated only with medium were used 
as control. After 24 h of incubation, 100 µl of fresh phenol free-DMEM (Thermofisher 
Scientific) containing 10% of cell counting kit 8 reagent (Sigma-Aldrich) were added to 
each well for 3 h at 37C. The amount of formazan dye generated, directly proportional 
to the number of live cells, was measured with Sinergy H1 microplate reader at 450 nm. 
Cell viability was calculated as the ratio of the absorbance of the samples incubated with 
GNPs to that of the control and expressed as percentage of untreated control cells. 
 
6.3 In vitro cancer cell targeting 
To investigate the specificity of particle binding, EGFR-positive GBM and EGFR-negative 
cells were grown into 8 wells chamber slide until confluence. Anti-EGFR or unconjugated 
GNPs were added to each well at the concentration range of 5-70 µg/ml over 24 h. 30 
min before the end of the incubation time, cells were incubated with 50 nM 
LysoTracker™ Deep Red (Thermofisher Scientific). To remove unbound GNPs, cells were 
washed three times with PBS for 10 min and fixed with 4% PFA for 10 min at RT. Staining 
of anti-EGFR GNPs was performed by using Alexa Fluor® 488 donkey anti-rabbit 
antibody (Abcam), diluted 1:250, for 1 h at RT. Cell nuclei were stained with 300 nM 
DAPI (Sigma-Aldrich) added to the secondary antibody. 
  
Raman measurements were carried out with confocal Raman alpha300 R microscope 
(Witec, GmbH, Germany) equipped with a 785 nm excitation wavelength. Laser power 
was set at 25 mW with an integration time of 0.05 sec, 50x objective. Raman maps were 
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generated by plotting the SERS signals of 1,4-BDT bands at 1’058 cm-1 and 1’556 cm-1. 
Fluorescence images were acquired from the same sample spots for comparison with 
their SERS images. For quantification of SERS signal, pictures of three random areas for 
each specimen were converted in 16-bit images and quantify with Image j software. 
Area (1’000 x 500 pixel), % area was used for comparison, gray value threshold 35-
65’535. 
 
Cellular distribution of anti-EGFR GNPs was investigated with laser confocal scanning 
microscope FV1000D (Olympus). Pictures were analyzed with Image J software. 
 
Dark field analysis was done using hyperspectral imaging system (VNIR Version, 
CytoViva, Inc, US). 
 
Cellular uptake of GNPs was investigated by transmission electron microscopy imaging. 
Briefly, 3.5 x 106 BS153 and IMA2.1 cells were seeded into 100-cm plate overnight. 10 
µg/ml of anti-EGFR or unconjugated GNPs were added for 4 h under agitation. Cells 
were washed three times with PBS for 10 min and fixed with 1:1 (v/v) medium-double 
strength fixative mixture for 20 min. Cells were harvested using a cell scraper and 
centrifuged at 600 rpm for 5 min. Supernatant was replaced with single strength fixative 
for at least 45 min. Cells were washed three times and resuspended in cold washing 
buffer. 
Double strength fixative in normal strength buffer (0.1 M): 4% PFA (Electron Microscope 
Science) + 5% Glutaraldehyde (GA, Electron Microscope Science) in 0.1 M piperazine-
N,N′-bis(2-ethanesulfonic acid) (PIPES, Sigma-Aldrich) buffer pH 7.0-7.2. Single strength 
fixative: 2% PFA + 2.5% GA in 0.1 M PIPES buffer pH 7.0-7.2. Washing buffer: 0.1M PIPES 
buffer pH7.0-7.2. 
The following steps were performed at the BioEM lab (C-Cina, University of Basel). Fixed 
cells were embedded in agarose (Sigma-Aldrich), post-fixed in 1% buffered osmium 
tetroxide (Electron Microscope Science) for 1 h at 4C and stained with aqueous uranyl 
acetate (Electron Microscope Science) for 1 h at 4C in the dark. Samples were 
dehydrated in an ethanol series (30, 50, 75, 95 and 100%), washed in acetone and finally 
embedded in pure Epon 812 resin (Electron Microscope Science) for 48 h at 60C. Cut 
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sections were placed on copper grids and observed with FEI Tecnai T12 transmission 
electron microscope operating at 80 kV. Images were recorded using a CCD Veleta 
digital camera. 
 
6.4 In vitro BBB model 
The human endothelial cell line hCMEC/D3 was provided by Prof. Luc Stoppini (Hepia- 
Haute ecole du paysage, d'ingenierie et d'architecture de Geneve, Geneva, Switzerland). 
Cells were cultured in EndoGROTM-MV complete medium Kit (Millipore, SCME004) 
supplemented with 1 ng/ml FGF-2 (Thermofisher Scientific) in flasks pre-coated with 
collagen type I solution diluted 1:20 (Sigma-Aldrich), and kept at 37°C, in a 5% CO2 
atmosphere. To establish the BBB model, 6.5 mm transwell with 0.4 μm pore polyester 
membrane inserts were used (Sigma, CLS3470). 2 x 104 cells were seeded on the apical 
surface of the membrane, pre-coated with collagen at density of 10 µg/cm2 and grown 
up to 12 days. 
 
6.4.1 Fluorescence staining of TJs 
Formation of a tight monolayer was evaluated by detecting the expression of TJs 
proteins ZO-1 and claudin-5. After 5 days of culture, inserts were fixed with 2% PFA for 
10 min at RT, permeabilized with 0.1% Triton X-100 in PBS for 5 min and blocked with 
3% BSA in PBS for 1 h at RT. Cells were incubated with Alexa Fluor® 488 mouse anti-
human ZO-1 (Invitrogen, ZO1-1A12) and rabbit anti-human claudin-5 antibodies 
(Abcam), diluted 1:50 and 1:100 respectively, overnight at 4°C, then with Alexa Fluor® 
546 goat anti-rabbit antibody (Invitrogen), diluted 1:500, for 45 min at RT. Cell nuclei 
were stained with 300 nM DAPI for 15 min at RT. Cells were mounted in FluorSave™ 
Reagent and pictures taken with an AxioCam MRm camera coupled to Axiovert 40 CFL 
microscope (Zeiss). Washings with PBS were performed between each step for 5 min 
each. 
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6.4.2 TEER measurement  
Beside traditional permeability assay, the formation of a continuous and tight 
monolayer was monitored by measuring the TEER. Inserts with hCMEC/D3 cells and with 
collagen only as control were placed into “cellware” plate, a prototype developed by 
the group of Prof. Luc Stoppini (Hepia, Geneva, Switzerland). It is provided with an 
adaptor to be used with CellZscope system (nanoAnalytics, GmbH). Since TEER values 
are highly temperature sensitive, the plate was placed in the incubator and let to 
equilibrate at 37°C overnight. The day after, values were recorded in real-time every 4 
h and analyzed with the CellZscope software. 
 
6.4.3 BBB permeability assay 
To assess the tightness of cell monolayer, paracellular permeability of LY CH dipotassium 
salt (Sigma-Aldrich) was investigated. Inserts with hCMEC/D3 cells and with collagen 
only as control were moved into new 24 wells plate containing 600 µl of pre-warmed 
cell culture medium. 100 µl of 10 µg/ml LY solution were added to the apical chamber 
of the insert and the plate was placed on an orbital shaker at 100 rpm, at 37°C for 1h. 
Then 100 µl aliquots were collected from the basolateral chamber and LY fluorescence 
was read at ʎex 428 nm and ʎem 540 nm with FlexStation 3 (Molecular Device, LCC). 
Amount of LY was determined using a calibration curve generated with known 
concentration of LY diluted in cell culture medium. Apparent permeability coefficient 
(Papp) was calculated in cm/s according to the following equation: Papp (cm/s) = 
VB/(ACAO) x (ΔCB/ΔT), where VB is the volume in the basolateral chamber, A is the surface 
area of the filter, CAO is the initial concentration in the apical chamber, ΔCB/ΔT is the 
change of concentration in the basolateral chamber over time. 
 
6.4.4 Permeation of GNPs through the BBB 
After 7 days of culture, the medium in the apical chamber was replaced with 150 l of 
10 or 35 g/ml of anti-EGFR GNPs to investigate their transport through the BBB. Plate 
was placed on an orbital shaker at 100 rpm at 37°C for 24 h. At the end of the incubation, 
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medium was collected from the basolateral compartment and the amount of gold 
measured by ICP-MS.  
 
6.5 Statistical analysis 
Data evaluation was performed with GraphPad Prism 8 (GraphPad Software, inc.) and 
results are presented as means ± standard deviation (SD) of three independent 
experiments, unless otherwise specified. The Student t test was used for comparison 
between two groups, P<0.05 was considered significant. Data from three or more 
groups were analyzed by one or two-way ANOVA analysis with Dunnet’s multiple 
comparisons test. 
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List of abbreviations 
  
Abbreviation Full name 
1,4-BDT  1,4-Benzenedithiol 
3D  Three dimensions 
5-ALA  5-aminolevulinic acid 
AMT  Absorption mediated transport 
aPEG  Amino polyethylene glycol methoxy 
BBB  Blood brain barrier  
BSA Bovine serum albumin 
BTB  Brain tumor barrier 
CARS  Coherent anti-Stokes Raman scattering 
cPEG  Carboxy polyethylene glycol thiol 
CT  Computerized tomography 
DMEM  Dulbecco’s modified Eagle’s medium 
DMSO  Dimethyl sulfoxide 
EDC  Ethyl dimethylaminopropyl carbodiimide 
EDTA  Ethylenediaminetetraacetic acid 
EGFR  Epidermal growth factor receptor 
EPR  Enhanced retention and permeability 
FCS  Fetal calf serum 
FECH  Ferrochelatase 
FUS  Focused ultrasound 
GA Glutaraldehyde 
GBM  Glioblastoma 
GNP  Gold nanoparticle 
HEPES  4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HO-1  Heme oxygenase-1 
ICG  Indocyanine green 
ICP-MS  Inductively coupled plasma mass spectrometry 
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IDH  Isocitrate dehydrogenase 
iMRI  Intraoperative magnetic resonance imaging 
iUS  Intraoperative ultrasonography 
LSPR  Localized surface plasmon resonance 
LY  Lucifer yellow  
MFI  Mean fluorescence intensity 
MG  Malachite green 
MGITC  Malachite green isothiocyanate 
mPEG  Methoxy polyethylene glycol thiol 
MRI Magnetic resonance imaging 
NDS Normal donkey serum 
NIR  Near-infrared 
NOS  Not otherwise specified 
OD Optical density 
P/S  Penicillin/streptomycin 
Papp  Apparent permeability 
PBS  Phosphate buffered saline 
PBS-T Phosphate buffered saline Tween 
PEG  Polyethylene glycol 
PET  Positron emission tomography 
PFA  Paraformaldehyde 
PIPES Piperazine-N,N′-bis(2-ethanesulfonic acid) 
PPIX  Protoporphyrin IX 
PVDF Polyvinylidene difluoride 
QD Quantum dot 
qFACS  Quantitative fluorescence-activated cell sorting 
RES  Reticuloendothelial system 
RMT  Receptor mediated transcytosis 
RRS  Resonance Raman scattering 
RT Room temperature 
SD  Standard deviation 
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SERRS  Surface enhanced resonance Raman spectroscopy 
SEHRS  Surface enhanced hyper Raman scattering 
SERS  Surface enhanced Raman spectroscopy 
SPR Surface plasmon resonance 
SRS  Stimulated Raman scattering 
Sulfo-NHS  N-hydroxysulfosuccinimide 
TEER  Transendothelial electrical resistance 
TERS  Tip enhanced Raman spectroscopy 
TJ  Tight junction 
TMZ  Temozolomide 
TTF  Tumor treating field 
UV-Vis Ultraviolet-visible 
WHO  World health organization 
ZO Zonula occludens 
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